Important News on Expanded Newborn Screening

As most of you are aware, SB 24 was passed in the 2005 Legislative Session to expand the number of conditions for which newborn screening is completed in Kentucky. The complete expansion will be effective December 31, 2005, and at that time a total of 29 conditions will be included on the screen which puts Kentucky in line with the national recommendation from the March of Dimes. Changes began in the newborn screening process effective July 2005 and the bullets below highlight important information for submitters of newborn screens and hospitals.

For All Submitters of Newborn Screens, including Hospitals:

- The new technology will detect disorders at 24 hours of age. The optimal specimen should be collected at 24 hours of age, but no later than 48 hours of age.
- If the infant is going to receive a blood transfusion, if possible, get the blood spot specimen prior to giving the transfusion even if the infant is not 24 hours of age.
- Antibiotics need to be documented on the filter paper card but will not automatically require a repeat.
- Demographic information and physician of record should be verified with the parent on the specimen to ensure that the physician and family can be contacted quickly in the situation of a positive screen.
- The specimen needs to be mailed to the state lab within 24 hours of collection, so the mail process at the submitting facility should examine their mailing procedure to assure entry into the USPS (United States Postal Service) as soon as possible after collection.
- There will be an educational presentation available on https://ky.train.org

Specific to Hospitals:

- Hospitals are required to have a newborn screening coordinator designated with the Department for Public Health Newborn Screening Program on an annual basis in January. Newborn Nursery nurse managers will be contacted to provide information.
- Hospitals will be required to implement a protocol to assure all newborns receive a newborn screening blood test and submit to the Department for Public Health.
- Hospitals will also be required to provide educational information to parents regarding newborn screening. This information is available on the HRSA website http://mchb.hrsa.gov/programs/default.htm and scroll down to Newborn Screening brochure.

Follow-Up:

Short Term follow-up for abnormal or unsatisfactory specimens is conducted by state staff at the Department for Public Health.

Abnormal Result

- The state lab notifies the follow-up staff of the abnormal result.
- The follow-up staff contacts the primary care physician listed on the NBS filter paper card by telephone with further action and faxes information to their office.
- The Department for Public Health contracts with University of Kentucky and the University of Louisville for specialty clinic referrals.

Unsatisfactory Specimen

- The laboratory staff mails out results either with a letter explaining to repeat only one test or if no letter is attached, the entire specimen needs to be repeated.
- If a repeat specimen is not received within 10 days, a letter is mailed to the parent explaining that no repeat has been received and to contact their baby’s PCP.
After analyzing the data on the T4 levels the new cut off value will be 5.0ug/dL effective December 5, 2005. We will continue to monitor this and may adjust further in the future.

Disorders included in the screen as of December 31, 2005 are:

Disorders of Amino Acid Metabolism:
1. Phenylketonuria (PKU)
2. Maple Syrup Urine Disease (MSUD)
3. Homocystinuria (HCY)
4. Citrullinemia (CIT)
5. Arginosuccinic acidemia (ASA)
6. Tyrosinemia type 1 (TYR 1)

Disorders of Fatty Acid Oxidation
7. Medium chain acyl-CoA dehydrogenase deficiency (MCAD)
8. Very long chain acyl-CoA dehydrogenase deficiency (VLCAD)
9. Long-chain hydroxyacyl-CoA dehydrogenase deficiency (LCHAD)
10. Short-chain acyl-CoA dehydrogenase deficiency (SCAD)
11. Trifunctional protein deficiency (TFP)
12. Carnitine uptake defect (CUD)

Disorders of Organic Acid Metabolism
13. Isovaleric acidemia (IVA)
14. Glutaric acidemia type 1 (GA 1)
15. 3-hydroxy-3-methyl glutaric aciduria (HMG)
16. Multiple carboxylase deficiency (MCD)
17. Methylmalonic acidemia (Cbl A, B)
18. Methylmalonic acidemia mutase deficiency (MUT)
19. Propionic Acidemia (PA)
20. β-ketothiolase deficiency (BKT)
21. 3-Methylcrotonyl-CoA carboxylase deficiency

Hemoglobinopathies
22. Sickle Cell Disease
23. Hemoglobin SC Disease
24. Hemoglobin S/β-thalassemia

Others
25. Galactosemia
26. Biotinidase deficiency
27. Congenital Adrenal Hyperplasia (CAH)
28. Cystic Fibrosis (CF)
29. Congenital Hypothyroidism (CH)

For more information contact Sandy Fawbush at 502-564-3756 Ext 3761 or sandy.fawbush@ky.gov

12/1/05 Update
902 KAR 4:030. Newborn Screening Program.

RELATES TO: KRS 214.155
STATUTORY AUTHORITY: KRS 194A.050, 211.090, 214.155
NECESSITY, FUNCTION, AND CONFORMITY: KRS 214.155 requires the Cabinet for Health and Family Services to operate a newborn screening program for inborn errors of metabolism and other inherited disorders, and to establish a schedule of fees to cover the actual costs to the cabinet for the program. This administrative regulation requires that infants be tested for inborn errors of metabolism and other inherited disorders as specified in KRS 214.155, and establishes the schedule of fees to cover actual costs of the Newborn Screening Program.

Section 1. Definitions. (1) "Laboratory" means the Division of Laboratory Services within the Cabinet for Health and Family Services, Department for Public Health.
(2) "Program" means the Newborn Screening Program for heritable disorders operated by the Cabinet for Health and Family Services, Department for Public Health.
(3) "Submitter" means any hospital, primary care provider, health department, birthing center, laboratory, or midwife submitting an infant’s blood specimen for the purpose of newborn screening.

Section 2. Tests for inborn errors of metabolism or other inherited disorders for newborn infants as part of newborn screening shall include the following tests:
(1) 3-methylcrotonyl-CoA carboxylase deficiency (3MCC);
(2) 3-OH 3-CH₃ glutaric aciduria (HMG);
(3) Argininosuccinic acidemia (ASA);
(4) Beta-ketothiolase deficiency (BKT);
(5) Biotinidase disorder;
(6) Carnitine uptake defect (CUD);
(7) Citrullinemia (CIT);
(8) Congenital adrenal hyperplasia (CAH);
(9) Congenital hypothyroidism;
(10) Cystic fibrosis (CF);
(11) Galactosemia;
(12) Glutaric acidemia type I (GA I);
(13) Hb S/beta-thalassemia (Hb S/Th);
(14) Hb S/C disease (Hb S/C);
(15) Homocystinuria (HCY);
(16) Isovaleric acidemia (IVA);
(17) Long-chain L-3-OH acyl-CoA dehydrogenase deficiency (LCHAD);
(18) Maple syrup urine disease (MSUD);
(19) Medium-chain acyl-CoA dehydrogenase deficiency (MCAD);
(20) Methylmalonic acidemia (Cbl A,B);
(21) Methylmalonic acidemia mutase deficiency (MUT);
(22) Multiple carboxylase deficiency (MCD);
(23) Phenylketonuria (PKU);
(24) Propionic acidemia (PA);
(25) Short-chain acyl-CoA dehydrogenase deficiency (SCAD);
(26) Sickle cell disease;
(27) Trifunctional protein deficiency (TFP);
(28) Tyrosinemia type I (TYR I); and
(29) Very long-chain acyl-CoA deficiency (VLCAD).

Section 3. Submitter Responsibilities. (1) Except as provided in KRS 214.155(4), the administrative officer, or other person in charge of the hospital or institution caring for newborn infants, and the attending physician or midwife shall administer to, or verify administration of tests to, every infant in its care, a blood test to detect inborn errors of metabolism or other inherited disorders identified in Section 2 of this administrative regulation prior to hospital discharge. If a baby is not born in a hospital or institution, the attending physician or midwife shall be responsible for ensuring that these tests are administered between twenty-four (24) and forty-eight (48) hours of age.
(2) A capillary blood specimen shall be obtained from a newborn infant, not requiring an extended stay due to illness or prematurity, between twenty-four (24) and forty-eight (48) hours of age.
(3) If the infant is to remain in the hospital due to illness or prematurity, the hospital shall obtain the capillary blood specimen from that infant after twenty-four (24) and before seventy-two (72) hours of age.
(4) If an infant is transferred from the birth hospital to another hospital during the newborn hospital stay, the following rules shall apply:
(a) The sending hospital shall obtain the capillary blood specimen for the newborn screening blood test if the infant is twenty-four (24) hours of age or more when the infant is transferred to another hospital.
(b) The receiving hospital shall ensure the newborn screening blood test is performed if the infant is less than twenty-four (24) hours of age when the infant is transferred.
(c) If the information on the filter paper specimen card obtained by the submitter and sent to the laboratory is incomplete or inadequate, then the submitter, upon request of the program, shall use all reasonable efforts to locate the infant and obtain a complete and adequate specimen within ten (10) days. If the submitter is unable to obtain the specimen within ten (10) days, this shall be reported to the program.

(6) that are responsible for the collection of the initial specimen for newborn screening shall:
(a) Provide to an infant’s parent or guardian educational materials regarding newborn screening;
(b) Designate a newborn screening coordinator and physician responsible for the coordination of the facility’s newborn screening compliance;
(c) Notify the program of the name of the individuals designated in subsection (6)(b) of this section each year in January and if the designated individual changes and;
(d) Develop a written protocol for tracking newborn screening compliance. This protocol shall be submitted to the program each year in January.

12/1/05 Update

-1C-
1. The protocol shall include a requirement that the name of the physician attending the infant after birth or discharge, or a designee be placed on the filter paper specimen card sent with the initial specimen to the laboratory.
2. The protocol shall include verification that each infant born at that facility has had a specimen obtained for newborn screening on or before discharge and notification shall occur to the program within seven (7) days if any infant is missed; and
3. The hospital or facility that identifies that an infant has not had a specimen obtained for newborn screening prior to discharge shall use every reasonable effort to locate the infant and recommend that they present to the hospital or their primary care provider for a newborn screening specimen to be obtained.

(e) Hospitals or facilities shall report all written refusals, in accordance with KRS 214.155(4), to the program within seven (7) days.

Section 4. Specimen Collection. (1) Capillary blood specimens required in Section 3 of this administrative regulation shall be obtained by a heel stick. Blood from the heel stick shall be applied directly to filter paper specimen card. All circles shall be saturated completely using a drop of blood per circle on a filter paper specimen card. The specimen collector shall provide, on the filter paper specimen card, information requested by the laboratory.

(2) The capillary blood specimen shall be air dried for three (3) hours and then shall be mailed or sent to the laboratory within twenty-four (24) hours of collection of the specimen or the next business day in which mail or delivery service is available.

(3) Submitters send submit blood specimens to the Cabinet for Health and Family Services, Department for Public Health, Division of Laboratory Services, P.O. Box 2010, Frankfort, Kentucky 40602.

(4) Specimens processed or tracked under the newborn screening program shall be limited to specimens on infants less than six (6) months of age.

Section 5. Unsatisfactory or Inadequate Specimen. (1) If a specimen is unsatisfactory or inadequate to produce a valid result, the laboratory shall notify the submitter and the primary care provider on the filter paper specimen card by mail that the newborn screening needs to be repeated as soon as possible.

(2) If a requested repeat specimen has not been received within ten (10) business days from the date the repeat request was issued, the laboratory shall notify the parent by mail of the need for a repeat screening test.

Section 6. Special Circumstances - Blood Transfusion. If a newborn infant requires a blood transfusion, the following rules for newborn screening shall apply:

(1) The hospital shall obtain a capillary blood sample for newborn screening prior to the infant being transfused, except in an emergency situation.

(2) If the pretransfusion sample was obtained before twenty-four (24) hours of age, or if it was not obtained due to an emergency situation, then the hospital or primary care provider shall use all reasonable efforts to obtain a repeat capillary blood specimen from the transfused infant and submit it to the laboratory according to the following schedule:
   (a) Seventy-two (72) hours after last blood transfusion, rescreen for inborn errors of metabolism and inherited disorders listed in Section 2 of this administrative regulation;
   (b) Ninety (90) days after last blood transfusion, rescreen for any disorder that relies on red blood cell analysis such as hemoglobinopathies, galactosemia, and biotinidase deficiency.

Section 7. Reporting of Results. (1) Normal Results. Upon receipt of normal lab results, the laboratory shall mail results to the primary care provider and the submitter.

(2) Abnormal Results.
   (a) Submitters and primary care providers shall receive a copy of all abnormal, presumptive positive, and equivocal results by mail.
   (b) In addition to receiving mailed results, primary care providers shall be notified of presumptive positive and equivocal results in the following manner:
      1. Upon receipt of a presumptive positive lab result the program shall immediately notify the primary care provider listed on the filter paper specimen card of the result and recommend appropriate follow-up testing.
      2. Upon receipt of an equivocal result, the program shall notify the primary care provider on the filter paper specimen card within two (2) business days of the result and next step recommendations.
      3. If the program is unable to ascertain a correct primary care provider for a specimen to be obtained, for repeat screen or referral, they shall contact the parent of the infant.
      (c) The Cabinet for Health and Family Services shall share pertinent test results with state university-based specialty clinics or primary care providers who inform the cabinet that they are treating the infant who received the test, and may share pertinent test results with the local health department in the infant’s county of residence that conducts newborn screening follow-up activities. These specialty clinics or primary care providers shall report results of diagnostic testing to the program within thirty (30) days or earlier upon request.
      (d) The laboratory shall report abnormal, presumptive positive, or equivocal results of tests for inherited disorders and inborn errors of metabolism to the program on behalf of the hospitals and submitters.
      (e) If a requested repeat specimen has not been received within ten (10) business days from the date the repeat request was issued, the program shall notify the parent by mail of the need for a repeat screening test.

Section 8. Newborn Screening Fees. (1) Submitters obtaining and sending a blood specimen to the laboratory shall be billed a fee of $53.50 for the initial newborn screening test.

(2) Submitters obtaining and sending a repeat blood specimen to the laboratory shall not be charged an additional fee of $53.50.

(3) Fees due the Cabinet for Health and Family Services shall be collected through a monthly billing system. (MCH-3; 1 Ky.R. 640; eff. 4-9-75; Am. 6 Ky.R. 314; eff. 1-2-80; 9 Ky.R. 366; 555; eff. 10-6-82; 11 Ky.R. 652; eff. 11-13-84; 13 Ky.R. 786; eff. 11-11-86; 14 Ky.R. 2066; eff. 6-22-98; 21 Ky.R. 578; eff. 9-21-94; 32 Ky.R. 2036; 1487; 2274; eff. 6-21-2006.)
Insert copy of your hospital protocol and submit a copy of protocol and the complete the contact information sheet for the Newborn Screening Coordinator at your facility and mail to:

Department for Public Health
Newborn Screening Program
275 East Main St HS 2GW-C
Frankfort, KY 40621
Newborn Screening Coordinator Information

Facility Name ______________________

Coordinator Name __________________

    Telephone Number __________________

    Email ______________________________

Completed by:

____________________________________  ______________________________________

    Name                                     Title

Please complete and fax to the Newborn Screening Program 502-584-1510.
PROPER SPECIMEN COLLECTION PROCEDURE

The filter paper forms should be stored in a cool, dry place. Be sure to take note of the form expiration date printed on the filter paper margin below the circles. The filter paper forms are to be used on or before the expiration date. Destroy all outdated forms immediately and request a new supply from the Kentucky Public Health Laboratory. Order no more forms than can be used in 6 months.

Gloves should be worn for personal safety. Care should be taken to avoid contamination of blood collection circles with antiseptic solutions, powders, lotions or other materials, which may adversely affect the testing process.

1. When collecting blood, fold back the cover sheet to expose the filter paper. Do not touch or handle the filter paper before or after applying blood.

2. Position the infant with feet lowered below the heart to help to increase the blood flow.

3. Warm the heel to increase the blood flow to the area by covering the puncture site for three to five minutes with a warm, moist towel which has been run under tap water at a temperature of not more than 42 degrees centigrade or 107.6 degrees F.

4. Clean the puncture site with a sterile alcohol pad. Allow to air dry. Excess alcohol may cause hemolysis and denature some of the enzymes tested.

5. Use a sterile disposable lancet with a 2.0 mm tip or an automatic lancet to perform a swift clean puncture in the areas indicated on the diagram. Wipe away the first drop of blood with dry sterile gauze.

Recommendation for Heel Puncture Site in Newborns:
Perform punctures on the most lateral portions of the plantar surface (in the hatched portion of the foot in the photo to the right).

6. Allow a large drop of blood to form. To enhance blood flow during collection, very gentle intermittent pressure may be applied to the area surrounding the puncture site. Excessive "milking" causes an admixture of tissue fluids with the blood specimen, resulting in an unsatisfactory specimen.

7. Do not use a capillary tube. Lightly touch the filter paper against a large drop of blood and allow a sufficient quantity of blood to soak through to completely fill the circle. Apply blood to one side of the filter paper only, allowing full saturation of each circle area. Either side may be chosen for this procedure. Fill all circle areas. Do not layer successive small drops of blood to the same circle. Avoid touching or smearing the blood spots.

8. If blood flow is diminished, repeat steps three through six with sterile equipment.

9. Special Considerations: Do not draw from intravenous lines where TPN or blood is being infused. For other types of IV fluids, make sure the line has been thoroughly flushed before attempting specimen collection. Avoid syringes with additives. Draw 2 to 2.5 cc from the line before sample is obtained. Spot the card immediately after specimen collection.

10. Allow the blood specimens to air-dry for at least 3 hours on a flat, nonabsorbent surface protected from heat or direct sunlight. Do not refrigerate the samples.

11. Ship collection forms to the Kentucky Public Health Laboratory after at least 3 hours drying time. Remember to “Draw, Dry, and Drop (in the mail).” Do not accumulate or "batch" specimens before shipping since this may result in specimens too old to test. When placing more than one specimen in an envelope, alternate orientation of collection forms so that blood spots on adjacent forms are not in contact. Delayed submission to the laboratory may result in significant delay in identification of an infant with a disorder.

12. After completing the form and collecting the specimen, ship to: Department for Public Health, Division of Laboratory Services, P. O. Box 2010, Frankfort, KY 40602.

The Kentucky Public Health Laboratory assumes responsibility for testing only; whoever submits specimens must assume liability for proper identification, collection and prompt delivery of specimens to the State Lab.

12/01/05 Update
Neonatal Screening Blood Specimen Collection and Handling Procedure

1. Equipment: Sterile lancet with tip approximately 2.0 mm, sterile alcohol prep, sterile gauze pads, soft cloth, blood form, gloves.

2. Complete ALL information. Do not contaminate filter paper circles by allowing the circles to come in contact with spillage or by touching before or after blood collection. Keep "SUBMITTER COPY" if applicable.

3. Hatched area (indicated) indicates safe area for puncture site.

4. Warm site with soft cloth, moistened with warm water up to 41°C, for three to five minutes.

5. Cleanse site with alcohol prep. Wipe DRY with sterile gauze pad.

6. Puncture heel. Wipe away first blood drop with sterile gauze pad. Allow another LARGE blood drop to form.

7. Lightly touch filter paper to LARGE blood drop. Allow blood to soak through and completely fill circle with SINGLE application to LARGE blood drop. (To enhance blood flow, VERY GENTLE intermittent pressure may be applied to area surrounding puncture site.) Apply blood to one side of filter paper only.

8. Fill remaining circles in same manner as step 7, with successive blood drops. If blood flow is diminished, repeat steps 5 through 7. Care of site puncture site should be consistent with your institution's procedures.

9. Dry blood spots on a dry, clean, flat, non-absorbent surface for a minimum of four hours.

10. Mail completed form to testing laboratory within 24 hours of collection.

Schleicher & Schuell

Information provided by New York State Department of Health
Simple Spot Check

Valid Specimen

Allow a sufficient quantity of blood to soak through to completely fill the preprinted circle on the filter paper. Fill all required circles with blood. Do not layer successive drops of blood or apply blood more than once in the same collection circle. Avoid touching or smearing spots.

Invalid Specimens

1. Specimen quantity insufficient for testing.
2. Specimen appears scratched or abraded.
3. Specimen not dry before mailing.
4. Specimen appears supersaturated.
5. Specimen appears diluted, discolored or contaminated.
6. Specimen exhibits serum rings.
7. Specimen appears clotted or layered.
8. No blood.

Possible Causes

- Removing filter paper before blood has completely filled circle or before blood has sealed through to second side.
- Applying blood to filter paper with a capillary tube.
- Touching filter paper before or after blood specimen collection with gloved or ungloved hands, hand lotion, etc.
- Allowing filter paper to come in contact with gloved or ungloved hands or substances such as hand lotion or powder, either before or after blood specimen collection.
- Applying blood with a capillary tube or other device.
- Mailing specimen before drying for a minimum of four hours.
- Applying excess blood to filter paper, usually with a device.
- Applying blood to both sides of filter paper.
- Squeezing or "milking" of area surrounding the puncture site.
- Allowing filter paper to come in contact with gloved or ungloved hands, or substances such as alcohol, antiseptic solutions, water, hand lotion or powder, etc., either before or after blood specimen collection.
- Exposing blood spots to direct heat.
- Not wiping alcohol from puncture site before making skin puncture.
- Allowing filter paper to come in contact with alcohol, hand lotion, etc.
- Squeezing area surrounding puncture site excessively.
- Drying specimen improperly.
- Applying blood to filter paper with a capillary tube.
- Touching the same circle on filter paper to blood drop several times.
- Filling circle on both sides of filter paper.
- Failure to obtain blood specimen.
The Kentucky Newborn Screening Brochure can be found at:


The Spanish Kentucky Newborn Screening Brochure can be found at:

http://chfs.ky.gov/NR/rdonlyres/EEDB5BF4-D7B7-4C59-AB5A-4C478B8D918E/0/ParentBrochureKYNBS2006_spa.pdf

Parent Brochures

These brochures can be printed out on legal paper for use by health care providers and parents.

Note: These documents are in Adobe Acrobat (.PDF) format. Please click on the following link to download a free copy of Adobe Acrobat Reader.

Parent Brochure for the KY Newborn Screening Program (English)  (PDF - 429k)

Parent Brochure for the KY Newborn Screening Program (Spanish)  (PDF - 488k)

9/27/06 Update
Laboratory Contact Information

YOU SHOULD RECEIVE AND OFFICIAL COPY OF THE NEWBORN SCREENING LAB RESULTS BUT SHOULD YOU NEED A COPY PLEASE FAX COMPLETED REQUEST FORM TO THE NUMBER BELOW:

FAX REQUEST FOR RESULTS: FAX # 502-564-2905

A COPY OF REQUEST FORM TO BE COMPLETED INCLUDED IN THIS BINDER.

TO ORDER SPECIMEN COLLECTION FORMS: 502-564-4446 EXT 4440
LABORATORY STAFF: 502-564-4446 EXT. 4434

Short Term Follow-Up (prior to university referral) Contact Information

Sandy Fawbush, RN: Phone: 502-564-3756 Ext. 3761
Troi Cunningham, RN 800-462-6122 Ext. 3761
Mary Sue Flora, RN sandy.fawbush@ky.gov

Newborn Screening Program Fax: 502-564-1510
PROVIDER FAX REQUEST
FOR LABORATORY INFORMATION

Date: ________________________

Please verify that all information below is completed accurately and legibly. We also request that you include a telephone number where you can be reached in the event we have questions and a fax number so you can receive the information you’ve requested. Thank you.

Infant Name: _______________________________ DOB: ___________ Sex: _________

Mother’s Name: ________________________________________________________

Mother’s SSN:  ________________________________

Requested Lab
Values:________________________________________________________________
_______________________________________________________________________

Who is making this request?

PCP Name: _____________________________________________________________

PCP Phone: (_____)______________________________________________________

PCP Fax # (so request can be processed):  ___________________________________

PCP Address: ___________________________________________________________
_______________________________________________________________________

CONFIDENTIALITY NOTE: This facsimile message is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure and under applicable law. If the reader of this message is not the intended recipient, you are notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone and return same to us at the above address via the U.S. Postal Service. Thank you.
# Newborn Screening Program

## Resources for Metabolic Disorders

**Amino Acid Disorders, Organic Acid and Fatty Acid Disorders**

<table>
<thead>
<tr>
<th>Clinic</th>
<th>Staff</th>
<th>Phone</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>University of Kentucky</strong></td>
<td>Carol Reid, MT (ASCP), MPA</td>
<td>(859) 323-5404</td>
</tr>
<tr>
<td>Lexington, KY</td>
<td>C. Charlton Mabry, MD</td>
<td>(859) 323-5404</td>
</tr>
<tr>
<td><strong>Primary Contact Number</strong></td>
<td>Carolyn Bay, MD</td>
<td>(859) 257-5559</td>
</tr>
<tr>
<td>(859) 323-5404</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Primary Contact</strong></td>
<td>Carol Reid</td>
<td></td>
</tr>
<tr>
<td>MT (ASCP), MPA</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Emergency after hours:</strong></td>
<td>(800) 888-5533</td>
<td>(Page metabolic/newborn screening physician)</td>
</tr>
<tr>
<td></td>
<td>(502) 852-3879</td>
<td></td>
</tr>
</tbody>
</table>

| **University of Louisville** | Joseph Hersh, MD            | (502) 852-5334               |
| Louisville, KY            | After hours pager # (502) 562-9914 |                              |
| **Primary Contact Number** | Gordon Gowans, MD           |                              |
| (502) 852-3879           | Alexander Asamoah, MD       |                              |
| **Primary Contact**      | Karen Kinkus, RD            |                              |
| Carol Reid               |                              |                              |
| MT (ASCP), MPA         |                              |                              |
| **Emergency after hours:** | (502) 852-7512              | (502) 562-9914 beeper        |
|                         | Jan Askren, RN              |                              |
| (502) 852-7512          |                              |                              |
| Fax: (502) 852-5753      |                              |                              |

University of Kentucky: Carol Reid, MT (ASCP), MPA. (859) 323-5404

C. Charlton Mabry, MD. (859) 323-5404

Carolyn Bay, MD. (859) 257-5559

**Emergency after hours:** (800) 888-5533 (Page metabolic/newborn screening physician)

University of Louisville: Joseph Hersh, MD. (502) 852-5334

After hours pager # (502) 562-9914

Gordon Gowans, MD. Alexander Asamoah, MD
# Newborn Screening Program

## Resources for Cystic Fibrosis

<table>
<thead>
<tr>
<th>Clinic</th>
<th>Staff</th>
<th>Phone</th>
</tr>
</thead>
</table>
| **University of Kentucky**  
Division of Pediatric Pulmonology | Carol Reid, MT, (ASCP), MPA………..(859) 323-5404 |       |
| Carol Reid  
MT (ASCP), MPA  
(859) 323-5404 | Michael Anstead, MD…………………..(859) 257-5536 |       |
| **Emergency after hour:**  
(800) 888-5533 (ask for pediatric pulmonology on call) | Jamshed F. Kanga, MD | Fax: (859) 257-1888 |

| **University of Louisville**  
Pediatric Pulmonary Medicine | Martha Eddy, CPNP…………………..(502) 629-8830 |       |
| Jan Askren, RN  
(502) 852-7512  
Fax: (502) 852-5753 | Ronald Morton, MD…………………..(502) 629-8830 |       |
| **Emergency after hours:** (502) 629-6000  
(Page pediatric pulmonology) | Nehm Eid, MD | Fax: (502) 629-7540 |
# Newborn Screening Program

## Resources for Endocrinology

(Congenital Adrenal Hyperplasia, Congenital Hypothyroidism)

<table>
<thead>
<tr>
<th>Clinic</th>
<th>Staff</th>
<th>Phone</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>University of Kentucky</strong></td>
<td>Carol Reid MT, (ASCP), MPA…</td>
<td>(859) 323-5404</td>
</tr>
<tr>
<td><em>(859) 323-5404</em></td>
<td>Jeff Lomenick, MD…………………</td>
<td><em>(859) 323-5404</em></td>
</tr>
<tr>
<td>Dept. of Pediatrics</td>
<td>Jackson Smith, MD</td>
<td></td>
</tr>
<tr>
<td>Endocrinology and Metabolism</td>
<td>Carol Reid MT, (ASCP), MPA…</td>
<td></td>
</tr>
<tr>
<td>Carol Reid</td>
<td>Jeff Lomenick, MD…………………</td>
<td></td>
</tr>
<tr>
<td>MT, (ASCP), MPA</td>
<td>Jackson Smith, MD</td>
<td></td>
</tr>
<tr>
<td>Fax: (859) 323-8179</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Emergency after hours: (800) 888-5533</strong></td>
<td><em>(ask for Pediatric Endocrinology)</em></td>
<td></td>
</tr>
<tr>
<td><strong>University of Louisville</strong></td>
<td>Lee Ann Tincher, RN……………</td>
<td><em>(502) 629-8821</em></td>
</tr>
<tr>
<td><em>(502) 629-8821</em></td>
<td>Michael Foster, MD……………….</td>
<td><em>(502) 629-8821</em></td>
</tr>
<tr>
<td><strong>Pediatric Endocrinology</strong></td>
<td>Aaron Davis, MD</td>
<td></td>
</tr>
<tr>
<td>Jan Askren, RN</td>
<td>Kellie Woodruff, ARNP</td>
<td></td>
</tr>
<tr>
<td><em>(502) 852-7512</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fax: (502) 852-5753</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Emergency after hours: 502-629-6000 or</strong></td>
<td><em>(Page pediatric endocrinology)</em></td>
<td></td>
</tr>
<tr>
<td><em>(800) 292-2759</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fax: <em>(502) 629-8824</em></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Newborn Screening Program

**Resources for Hemoglobinopathies**

(Hb S/S, Hb S/A, Hb S/C)

<table>
<thead>
<tr>
<th>Clinic</th>
<th>Staff</th>
<th>Phone</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>University of Kentucky</strong></td>
<td>Elizabeth Lewis, RN, CPON......(859) 323-7705</td>
<td></td>
</tr>
<tr>
<td>Pediatric Hematology/Oncology</td>
<td>Carol Reid, MT (ASCP), MPA</td>
<td>(859) 323-5404</td>
</tr>
<tr>
<td>Phone: (859) 323-8075</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Emergency after hours:</strong></td>
<td></td>
<td>Fax: (859) 257-8978</td>
</tr>
<tr>
<td>(800) 888-5533</td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>(ask for pediatric hematology)</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>University of Louisville</strong></td>
<td>Diane Burnett, PNP ...............(502) 629-7750</td>
<td></td>
</tr>
<tr>
<td>Pediatric Hematology/Oncology</td>
<td>Jan Askren, RN</td>
<td>(502) 852-7512</td>
</tr>
<tr>
<td>Phone (502) 629-7750</td>
<td>Salvatore Bertelone, MD ...........(502) 629-7750</td>
<td></td>
</tr>
<tr>
<td>Jan Askren, RN</td>
<td></td>
<td>Fax: (502) 852-5753</td>
</tr>
<tr>
<td>(502) 852-7512</td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>(Page pediatric hematology)</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Emergency after hours:</strong></td>
<td></td>
<td>Fax: (502) 629-7784</td>
</tr>
<tr>
<td>(502) 629-6000</td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>(Page pediatric hematology)</em></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
# Newborn Screening Program

## Resources for Newborn Hearing and Screening

<table>
<thead>
<tr>
<th>Location</th>
<th>Clinic</th>
<th>Consultant</th>
<th>Phone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Louisville, KY</td>
<td>Commission for Children with Special Health Care Needs</td>
<td>Karen Mercer, RN</td>
<td>(877) 757-4327</td>
</tr>
<tr>
<td></td>
<td>982 Eastern Parkway</td>
<td></td>
<td>(800) 232-1160 Ext. 323</td>
</tr>
<tr>
<td></td>
<td>Louisville, KY 40217</td>
<td>Michelle King</td>
<td>(877) 757-4327 (HEAR) Ext. 258</td>
</tr>
<tr>
<td></td>
<td>(877) 757-4327</td>
<td></td>
<td>(800) 232-1160 Ext. 323</td>
</tr>
<tr>
<td>Central Region</td>
<td>Commission for Children with Special Health Care Needs</td>
<td>Eric Cahill</td>
<td>(800) 232-1160 Ext. 322</td>
</tr>
<tr>
<td></td>
<td>982 Eastern Parkway</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Louisville, KY 40217</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(800) 232-1160</td>
<td></td>
<td></td>
</tr>
<tr>
<td>East Region</td>
<td>Commission for Children with Special Health Care Needs</td>
<td>Lou Ann Jones</td>
<td>(800) 817-3874 Ext. 225</td>
</tr>
<tr>
<td></td>
<td>333 Waller Ave. Ste 300</td>
<td></td>
<td>(859) 225-7155</td>
</tr>
<tr>
<td></td>
<td>Lexington, KY 40504</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(800) 817-3874</td>
<td></td>
<td></td>
</tr>
<tr>
<td>West Region</td>
<td>Commission for Children with Special Health Care Needs</td>
<td>Carolyn Kisler</td>
<td>(800) 727-9903</td>
</tr>
<tr>
<td></td>
<td>712 West 15th St.</td>
<td></td>
<td>(270) 889-6050</td>
</tr>
<tr>
<td></td>
<td>Hopkinsville, KY 42240</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(800) 727-9903</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test name</td>
<td>Test Abbreviation</td>
<td>Category</td>
<td></td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>-------------------</td>
<td>-------------------------</td>
<td></td>
</tr>
<tr>
<td>2-Methyl 3-hydroxy butyric aciduria</td>
<td>2M3HBA</td>
<td>Organic Acid Disorders</td>
<td></td>
</tr>
<tr>
<td>3-Methylglutaconic aciduria</td>
<td>3MGA</td>
<td>Organic Acid Disorders</td>
<td></td>
</tr>
<tr>
<td>3-methylcrotonyl CoA Carboxylase deficiency</td>
<td>3MCC</td>
<td>Organic Acid Disorders</td>
<td></td>
</tr>
<tr>
<td>Argininemia</td>
<td>ARG</td>
<td>Amino Acid Disorders</td>
<td></td>
</tr>
<tr>
<td>Argininosuccinic Acidemia</td>
<td>ASA</td>
<td>Amino Acid Disorders</td>
<td></td>
</tr>
<tr>
<td>Benign Hyperphenylalaninemia</td>
<td>H-PHE</td>
<td>Amino Acid Disorders</td>
<td></td>
</tr>
<tr>
<td>Beta ketothiolase deficiency</td>
<td>BKT</td>
<td>Organic Acid Disorders</td>
<td></td>
</tr>
<tr>
<td>Biotinidase Deficiency</td>
<td>BIO</td>
<td>Other</td>
<td></td>
</tr>
<tr>
<td>Carnitine/acylcarnitine translocase deficiency</td>
<td>CACT</td>
<td>Fatty Acid Oxidation</td>
<td></td>
</tr>
<tr>
<td>Carnitine palmitoyltransferase II deficiency</td>
<td>CPT-2</td>
<td>Fatty Acid Oxidation</td>
<td></td>
</tr>
<tr>
<td>Carnitine uptake defect</td>
<td>CUD</td>
<td>Fatty Acid Oxidation</td>
<td></td>
</tr>
<tr>
<td>Citrullinemia</td>
<td>CIT</td>
<td>Amino Acid Disorders</td>
<td></td>
</tr>
<tr>
<td>Citrullinemia type II</td>
<td>CITII</td>
<td>Amino Acid Disorders</td>
<td></td>
</tr>
<tr>
<td>Congenital Adrenal Hyperplasia</td>
<td>CAH</td>
<td>Endocrine</td>
<td></td>
</tr>
<tr>
<td>Congenital Hypothyroidism</td>
<td>CH</td>
<td>Endocrine</td>
<td></td>
</tr>
<tr>
<td>Cystic Fibrosis</td>
<td>CF</td>
<td>Other</td>
<td></td>
</tr>
<tr>
<td>Ethylmalonic encephalopathy</td>
<td>EE</td>
<td>Fatty Acid Oxidation</td>
<td></td>
</tr>
<tr>
<td>Galactosemia</td>
<td>GALT</td>
<td>Other</td>
<td></td>
</tr>
<tr>
<td>Glutaric acidemia type 1</td>
<td>GA-1</td>
<td>Organic Acid Disorders</td>
<td></td>
</tr>
<tr>
<td>Glutaric acidemia type 2</td>
<td>GA-2</td>
<td>Organic Acid Disorders</td>
<td></td>
</tr>
<tr>
<td>Hemoglobin S-βeta thalassemia</td>
<td>Hb S/Th</td>
<td>Hemoglobin</td>
<td></td>
</tr>
<tr>
<td>Hemoglobin S/C disease</td>
<td>Hb S/C</td>
<td>Hemoglobin</td>
<td></td>
</tr>
<tr>
<td>Homocystinuria</td>
<td>HCY</td>
<td>Amino Acid Disorders</td>
<td></td>
</tr>
<tr>
<td>Hydroxymethylglutaric aciduria (3-OH 3-CH3 glutaric aciduria)</td>
<td>HMG</td>
<td>Organic Acid Disorders</td>
<td></td>
</tr>
<tr>
<td>Hypermethioninemia</td>
<td>MET</td>
<td>Amino Acid Disorders</td>
<td></td>
</tr>
<tr>
<td>Isobutyryl-CoA dehydrogenase deficiency</td>
<td>IBG</td>
<td>Fatty Acid Oxidation</td>
<td></td>
</tr>
<tr>
<td>Isovaleric acidemia</td>
<td>IVA</td>
<td>Organic Acid Disorders</td>
<td></td>
</tr>
<tr>
<td>Long-chain L-3hydroxyacyl-CoA dehydrogenase</td>
<td>LCHAD</td>
<td>Fatty Acid Oxidation</td>
<td></td>
</tr>
<tr>
<td>Malonic aciduria</td>
<td>MAL</td>
<td>Organic Acid Disorders</td>
<td></td>
</tr>
<tr>
<td>Maple Syrup Urine Disease</td>
<td>MSUD</td>
<td>Amino Acid Disorders</td>
<td></td>
</tr>
<tr>
<td>Medium-chain acyl-CoA dehydrogenase deficiency</td>
<td>MCAD</td>
<td>Fatty Acid Oxidation</td>
<td></td>
</tr>
<tr>
<td>Methylmalonic acidemia</td>
<td>Cbl A, B</td>
<td>Organic Acid Disorders</td>
<td></td>
</tr>
<tr>
<td>Methylmalonic acidemia mutase deficiency</td>
<td>MUT</td>
<td>Organic Acid Disorders</td>
<td></td>
</tr>
<tr>
<td>Multiple carboxylase deficiency</td>
<td>MCD</td>
<td>Organic Acid Disorders</td>
<td></td>
</tr>
<tr>
<td>Other variant Hb-pathies (including Hb E)</td>
<td>Var Hb</td>
<td>Hemoglobin</td>
<td></td>
</tr>
<tr>
<td>Phenylketonuria</td>
<td>PKU</td>
<td>Amino Acid Disorders</td>
<td></td>
</tr>
<tr>
<td>Propionic Acidemia</td>
<td>PA</td>
<td>Organic Acid Disorders</td>
<td></td>
</tr>
<tr>
<td>Short-chain acyl-CoA dehydrogenase deficiency</td>
<td>SCAD</td>
<td>Fatty Acid Oxidation</td>
<td></td>
</tr>
<tr>
<td>Sickle cell disease</td>
<td>HB S/S</td>
<td>Hemoglobin</td>
<td></td>
</tr>
<tr>
<td>Trifunctional protein deficiency</td>
<td>TFP</td>
<td>Fatty Acid Oxidation</td>
<td></td>
</tr>
<tr>
<td>Tyrosinemia type I</td>
<td>TYR I</td>
<td>Amino Acid Disorders</td>
<td></td>
</tr>
<tr>
<td>Tyrosinemia type II</td>
<td>TYRII</td>
<td>Amino Acid Disorders</td>
<td></td>
</tr>
<tr>
<td>Tyrosinemia type III</td>
<td>TYRIII</td>
<td>Amino Acid Disorders</td>
<td></td>
</tr>
<tr>
<td>Very long-chain acyl-CoA dehydrogenase deficiency</td>
<td>VLCAD</td>
<td>Fatty Acid Oxidation</td>
<td></td>
</tr>
</tbody>
</table>
The links to the following Fact Sheets can be found at this link on the internet:
http://chfs.ky.gov/dph/ach/ecd/newbornscreening.htm
<table>
<thead>
<tr>
<th><strong>Disease Name</strong></th>
<th>3-methylcrotonyl-CoA carboxylase deficiency</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Alternate name(s)</strong></td>
<td>3-methylcrotonylglycinuria</td>
</tr>
<tr>
<td><strong>Acronym</strong></td>
<td>3-MCC</td>
</tr>
<tr>
<td><strong>Disease Classification</strong></td>
<td>Organic Acid Disorder</td>
</tr>
<tr>
<td><strong>Variants</strong></td>
<td>Late-onset form</td>
</tr>
<tr>
<td><strong>Variant name</strong></td>
<td>Late-onset 3-methylcrotonyl-CoA carboxylase deficiency</td>
</tr>
<tr>
<td><strong>Symptom onset</strong></td>
<td>Many individuals remain asymptomatic into adulthood. Others present in late infancy (generally after 3 months).</td>
</tr>
<tr>
<td><strong>Symptoms</strong></td>
<td>Infants can present with a Reye-like syndrome of ketoacidosis, hypoglycemia, hyperammonemia which can lead to seizures, coma and possibly death. Others present with failure to thrive, hypotonia or spasticity. Late-onset 3-MCC may present as developmental delay without Reye-like syndrome. Symptomatic adults often report general weakness and fatigue. Many individuals are asymptomatic.</td>
</tr>
<tr>
<td><strong>Natural history without treatment</strong></td>
<td>Primary manifestations appear to be muscular hypotonia and atrophy. Individuals with Reye-like illnesses may die or suffer neurologic insult during these episodes.</td>
</tr>
<tr>
<td><strong>Natural history with treatment</strong></td>
<td>Once over the initial crisis, most individuals have been intellectually normal. It is uncertain whether treatment modifies disease course.</td>
</tr>
<tr>
<td><strong>Treatment</strong></td>
<td>Protein restricted diet. Leucine-free medical foods. Possible carnitine supplementation. Giving treatment to asymptomatic individuals is of questionable value.</td>
</tr>
<tr>
<td><strong>Emergency Medical Treatment</strong></td>
<td>See sheet from American College of Medical Genetics (attached) or for more information, go to website: <a href="http://www.acmg.net/resources/policies/ACT/ACT-sheet_C5-OH_4-29-06.pdf">http://www.acmg.net/resources/policies/ACT/ACT-sheet_C5-OH_4-29-06.pdf</a></td>
</tr>
<tr>
<td><strong>Other</strong></td>
<td>Newborn screening has led to the diagnosis of asymptomatic women whose infants have transiently elevated isovalerylcarnitine.</td>
</tr>
<tr>
<td><strong>Physical phenotype</strong></td>
<td>None</td>
</tr>
<tr>
<td><strong>Inheritance</strong></td>
<td>Autosomal recessive</td>
</tr>
<tr>
<td><strong>General population incidence</strong></td>
<td>1:50,000</td>
</tr>
<tr>
<td><strong>Ethnic differences</strong></td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Missing Enzyme</strong></td>
<td>3-methylcrotonyl-CoA carboxylase</td>
</tr>
<tr>
<td><strong>MS/MS Profile</strong></td>
<td>C5:1 (tigyl or 3-methylcrotonyl carnitine) elevated C5-OH (3-hydroxy-2-methylbutyryl carnitine)- elevated</td>
</tr>
<tr>
<td><strong>Genetests Link</strong></td>
<td><a href="http://www.genetests.org">www.genetests.org</a></td>
</tr>
</tbody>
</table>
### Disease Name
**Argininosuccinic Acidemia**

### Alternate name(s)
- Argininosuccinase deficiency
- Argininosuccinic aciduria
- Argininosuccinic acid lyase deficiency
- ASL deficiency
- Argininosuccinyl-CoA lyase deficiency

### Acronym
**ASAL**

### Disease Classification
**Amino Acid Disorder**

### Variants
Yes

### Variant name
Late onset form

### Symptom onset
Neonatal onset is typical, although later-onset may occur.

### Symptoms
- Anorexia, vomiting, lethargy, seizures and coma possibly leading to death.

### Natural history without treatment
Mental and physical retardation due to hyperammonemia, cyclic vomiting, seizures, cerebral edema and trichorrhexis nodosa. Coma and death possible.

### Natural history with treatment
Normal mental and physical development is possible if treatment is initiated before hyperammonemic crisis.

### Treatment
- Protein restricted diet
- Arginine supplementation to help complete the urea cycle
- Essential amino acid supplementation
- Ammonia scavenging drugs in some cases and supplemental carnitine if patient has a secondary deficiency.

### Emergency Medical Treatment
See sheet from American College of Medical Genetics (attached) or for more information, go to the website:
http://www.acmg.net/resources/policies/ACT/Act-Sheet-Citrullinemia_5-2-06_ljo.pdf

### Other
- Enzyme is genetically heterogeneous and patients may present in infancy/childhood with MR or seizures.
- Trichorrhexis nodosa (short, dry, brittle hair) in older patients.

### Enzyme location
Erythrocytes, liver and fibroblasts

### Enzyme Function
Catalyzes the conversion of argininosuccinate to fumurate and arginine as part of the urea cycle.

### Missing Enzyme
Argininosuccinate lyase

### Metabolite changes
Hyperammonemia

### Prenatal testing
- Enzyme assay in cultured amniocytes. DNA possible if mutations known.
- Analyte testing of amniocytes.

### MS/MS Profile
Citrulline is elevated, may show elevated argininosuccinic peak.

### OMIM Link

### Genetests Link
www.genetests.org

### Support Group
- National Urea Cycle Disorders Foundation
  http://www.nucdf.org/
- National Coalition for PKU and Allied Disorders
  http://www.pku-allieddisorders.org/
- Children Living with Inherited Metabolic Diseases
  http://www.climb.org.uk/

---

9/15/06 Update
# Health Care Provider Fact Sheet

## Disease Name

**Beta-ketothiolase deficiency**

## Alternate name(s)

Alpha-methylacetoacetic aciduria, 2-methyl-3-hydroxybutyric acidemia, Mitochondrial acetoacetyl-CoA thiolase deficiency, MAT deficiency, T2 deficiency, 3-oxothiolase deficiency, 3-ketothiolase deficiency, 3-KTD deficiency

## Acronym

BKD

## Disease Classification

Organic Acid Disorder

## Variants

No, but there is considerable clinical heterogeneity

## Variant name

N/A

## Symptom onset

Late infancy or childhood. Mean age at presentation is 15 months (range 3 days to 48 months). There are documented cases of asymptomatic patients with enzyme deficiency. Frequency of decompensation attacks falls with age and is uncommon after the age of 10.

## Symptoms

Symptoms include intermittent episodes of severe metabolic acidosis and ketosis accompanied by vomiting (often hematemesis), diarrhea and coma that may progress to death. There is great clinical heterogeneity between patients. Infancy is the period of highest risk for decompensation. Death or neurologic complications can occur. Neurologic damage includes striatal necrosis of the basal ganglia, dystonia and/or mental retardation. Other symptoms include cardiomyopathy, prolonged QT interval, neutropenia, thrombocytopenia, poor weight gain, renal failure and short stature. If neurologically intact, patients are normal between episodes.

## Natural history without treatment

Clinical outcome varies widely with a few patients suffering severe psychomotor retardation or death as a result of their initial attack and others with normal development and no episodes of acidosis.

## Natural history with treatment

Despite severe recurrent attacks, appropriate supportive care can result in normal development.

## Treatment


## Emergency Medical Treatment

See sheet from American College of Medical Genetics (attached) or for more information, go to website:  
http://www.acmg.net/resources/policies/ACT/ACT-sheet_C5-OH_4-29-06.pdf

## Physical phenotype

No dysmorphisms

## Inheritance

Autosomal recessive

## General population incidence

unknown

## Ethnic differences

None known

## Population

N/A

## Ethnic incidence

N/A

## Enzyme location

Converts 2-methylacetoacetyl-CoA to propionyl-CoA and acetyl-CoA.

## Enzyme Function

Catalyzes the decarboxylation of oxoacids.

## Missing Enzyme

Mitochondrial acetoacetyl-CoA thiolase enzyme

## Metabolite changes

Increased urinary excretion of 2-methyl-3-hydroxybutyric acid, 2-methylacetoacetic acid, tiglylglycine, 2-butanone, and ketone bodies (acetoacetic acid, 3-hydroxybutyric acid).

## Prenatal testing

Enzyme analysis in amniocytes or CVS tissue. If mutations have been identified, DNA testing is possible.

## MS/MS Profile

C5:1 tiglycarnitine – elevated

## OMIM Link


## Genetests Link

www.genetests.org

## Support Group

Organic Acidemia Association  
www.oaanews.org  
Save Babies through Screening Foundation  
www.savebabies.org  
Genetic Alliance  
www.geneticalliance.org

9/15/06 Update
Disease Name: Biotinidase Deficiency

Alternate name(s): MULTIPLE CARBOXYLASE DEFICIENCY, LATE-ONSET
MULTIPLE CARBOXYLASE DEFICIENCY, JUVENILE-ONSET
BTD DEFICIENCY

Acronym: BIOT

Disease Classification: Metabolic Disorder

Symptom onset: Prior to 12 months of age

Symptoms: In the untreated state, profound biotinidase deficiency during infancy is usually characterized by neurological and cutaneous findings that include seizures, hypotonia, and rash, often accompanied by hyperventilation, laryngeal stridor, and apnea. Older children may also have alopecia, ataxia, developmental delay, neurosensory hearing loss, optic atrophy, and recurrent infections. Individuals with partial biotinidase deficiency may have hypotonia, skin rash, and hair loss, particularly during times of stress. All symptomatic children improve when treated with 5 to 10 mg of oral biotin per day.

Natural history without treatment: Prolonged symptoms prior to institution of biotin therapy may leave the patient with varying degrees of neurological sequelae, including mental retardation, seizures, and coma. Death may result from untreated profound biotinidase deficiency.

Natural history with treatment: If treated promptly, biotinidase deficiency may be asymptomatic.

Treatment: Biotin supplement daily

Emergency medical treatment: See sheet from American College of Medical Genetics (attached) or for more information, go to website: http://www.acmg.net/resources/policies/ACT/ACT_sheet-biotinidase_4-28-06_ljo.pdf

Inheritance: Autosomal recessive

General population incidence: 1:60,000 estimated with either profound or partial deficiency


Genetests Link: www.geneclinics.org

Support Group: Biotinidase Family Support Group
http://biotinidasedeficiency.20m.com/

Children Living with Inherited Metabolic Diseases
http://www.climb.org.uk/
### Disease Name
Carnitine uptake deficiency

### Alternate name(s)
Systemic carnitine deficiency, Carnitine deficiency, Carnitine transporter deficiency

### Acronym
SCD, CUD

### Disease Classification
Fatty Acid Oxidation Disorder

### Variants
N/A

### Variant name
N/A

### Symptom onset
Infancy or childhood with fasting hypoglycemia, weakness and/or cardiomyopathy.

### Symptoms
Hypoketotic hypoglycemia, seizures, vomiting, lethargy progressing to coma. Chronic muscle weakness, cardiomyopathy, hepatomegaly.

### Natural history without treatment
Non-progressive developmental delay due to hypoglycemia, cardiomyopathy and muscle weakness.

### Natural history with treatment
Developmental delay, if present, is not reversed by treatment. Cardiomyopathy and muscle weakness can be reversed by treatment.

### Treatment
Carnitine supplementation, no fasting.

### Emergency Medical Treatment
See sheet from American College of Medical Genetics (attached) or for more information, go to website: http://www.acmg.net/resources/policies/ACT/ACT_sheet_C0_5-3-06_ljo.pdf

### Physical phenotype
Cardiomyopathy, muscle weakness.

### Inheritance
Autosomal recessive

### General population incidence
1/40,000

### Ethnic differences
No

### Population
N/A

### Ethnic incidence
N/A

### Enzyme location
Muscle, heart, kidney, leukocytes and fibroblasts

### Enzyme Function
Transports carnitine into cells

### Missing Enzyme
Carnitine transporter

### Metabolite changes
Decreased free carnitine in plasma, increased carnitine in urine, decreased carnitine in muscle.

### Prenatal testing
Protein analysis in cultured amniocytes, biochemical analyte testing. If a mutation in a proband is detected, DNA prenatal diagnosis via CVS or amniocytes is possible.

### MS/MS Profile
Reduced concentrations of free carnitine and various acylcarnitine species.

### OMIM Link

### Genetests Link
www.genetests.org

### Support Group
FOD Family Support Group
http://www.fodsupport.org

Save Babies through Screening Foundation
http://www.savebabies.org

Genetic Alliance
http://www.geneticalliance.org
<table>
<thead>
<tr>
<th>Disease Name</th>
<th>Citrullinemia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alternate name(s)</td>
<td>Argininosuccinic acid synthetase deficiency</td>
</tr>
<tr>
<td>Acronym</td>
<td>ASAS</td>
</tr>
<tr>
<td>Disease Classification</td>
<td>Amino Acid Disorder</td>
</tr>
<tr>
<td>Variants</td>
<td>Yes</td>
</tr>
<tr>
<td>Variant name</td>
<td>Citrullinemia type II (adult and neonatal onset forms) – caused by SLC25A13 mutations</td>
</tr>
<tr>
<td>Symptom onset</td>
<td>Neonatal with some variability</td>
</tr>
<tr>
<td>Symptoms</td>
<td>Potential lethal coma, seizures, anorexia, vomiting, lethargy, apnea and hypertonia. Possible enlarged liver.</td>
</tr>
<tr>
<td>Natural history without treatment</td>
<td>Mental retardation due to hyperammonemia.</td>
</tr>
<tr>
<td>Natural history with treatment</td>
<td>Normal IQ and development are possible if no damage from initial or subsequent hyperammonemic episodes.</td>
</tr>
<tr>
<td>Treatment</td>
<td>Management of hyperammonemomic cases with sodium benzoate and/or phenylacetate and arginine. Dietary restriction of protein, arginine and essential amino acid supplementation.</td>
</tr>
<tr>
<td>Emergency Medical Treatment</td>
<td>See sheet from American College of Medical Genetics (attached) or for more information, go to website: <a href="http://www.acmg.net/resources/policies/ACT/Act-Sheet-Citrullinemia_5-2-06_ljo.pdf">http://www.acmg.net/resources/policies/ACT/Act-Sheet-Citrullinemia_5-2-06_ljo.pdf</a></td>
</tr>
<tr>
<td>Physical phenotype</td>
<td>None</td>
</tr>
<tr>
<td>Inheritance</td>
<td>Autosomal recessive</td>
</tr>
<tr>
<td>General population incidence</td>
<td>Rare</td>
</tr>
<tr>
<td>Ethnic differences</td>
<td>Yes</td>
</tr>
<tr>
<td>Population</td>
<td>Citrullinemia type II is common in Japan</td>
</tr>
<tr>
<td>Ethnic incidence</td>
<td>N/A</td>
</tr>
<tr>
<td>Enzyme location</td>
<td>Widely expressed in tissues; liver, kidney and fibroblasts.</td>
</tr>
<tr>
<td>Enzyme Function</td>
<td>Catalyzes the conversion of citrulline and aspartic acid to argininosuccinic acid.</td>
</tr>
<tr>
<td>Missing Enzyme</td>
<td>Argininosuccinic acid synthetase</td>
</tr>
<tr>
<td>Metabolite changes</td>
<td>Hyperammonemia</td>
</tr>
<tr>
<td>Prenatal testing</td>
<td>Linkage analysis and enzyme testing</td>
</tr>
<tr>
<td>MS/MS Profile</td>
<td>N/A</td>
</tr>
<tr>
<td>Genetests Link</td>
<td><a href="http://www.genetests.org">www.genetests.org</a></td>
</tr>
</tbody>
</table>
Disease Name: Congenital Adrenal Hyperplasia

Acronym: CAH
Disease Classification: Endocrine Disorder

Symptom onset: INFANTS WITH CAH DO NOT APPEAR ILL AT BIRTH, BUT MAY, WITHIN THE FIRST FEW WEEKS OF LIFE, EXPERIENCE A SALT-LOSING CRISIS WHICH CAN LEAD TO SERIOUS ILLNESS AND DEATH.

Symptoms: Congenital adrenal hyperplasia (CAH) results from a deficiency in one or another of the enzymes of cortisol biosynthesis. In about 95% of cases, 21-hydroxylation is impaired in the zona fasciculata of the adrenal cortex so that 17-hydroxyprogesterone (17-OHP) is not converted to 11-deoxycortisol. Because of defective cortisol synthesis, ACTH levels increase, resulting in overproduction and accumulation of cortisol precursors, particularly 17-OHP, proximal to the block. This causes excessive production of androgens, resulting in virilization.

Natural history without treatment: If untreated, children with CAH will experience abnormally rapid growth early in childhood (but stunted in the long run) and early appearance of body hair. Babies with the salt-wasting form of CAH (about 75 percent of cases) are at risk for rapid, uncontrolled loss of salt from the body that can result in death. The imbalance of hormones before birth may cause some girls to have ambiguous genitalia.

Treatment: Daily supplements of the hormone cortisol, and in many cases a salt-retaining hormone. To prevent problems, treatment must begin shortly after birth.

Emergency Medical Treatment: See sheet from American College of Medical Genetics (attached) or for more information, go to website: http://www.acmg.net/resources/policies/ACT/Act_sheet_CAH_4-28-06_ljo.pdf

Physical phenotype: Ambiguous genitalia in females
Inheritance: Autosomal recessive
General population incidence: 1 in 21,500

Genetests Link: www.genetests.org

MAGIC Foundation for Children’s growth (MAGIC) http://www.magicfoundation.org
National Organization for Rare Diseases http://www.rarediseases.org
<table>
<thead>
<tr>
<th>Disease Name</th>
<th>Congenital Hypothyroidism</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acronym</td>
<td>CH</td>
</tr>
<tr>
<td>Disease Classification</td>
<td>Endocrine Disorder</td>
</tr>
<tr>
<td>Symptom onset</td>
<td>Clinical signs of hypothyroidism often do not appear until the infants is 3-4 months of age, thus it is most likely that affected infants will have already suffered irreversible brain damage before signs of the disease begin to appear. Many times the early diagnosis relies almost solely on the results of the newborn screening.</td>
</tr>
<tr>
<td>Symptoms</td>
<td>An affected infant may have prolonged neonatal jaundice, growth failure, lethargy, poor appetite and constipation.</td>
</tr>
<tr>
<td>Natural history without treatment</td>
<td>Even mild hypothyroidism can lead to severe mental retardation and growth retardation if untreated. Development is delayed early on, often indicated by failure to meet normal milestones.</td>
</tr>
<tr>
<td>Treatment</td>
<td>Daily oral thyroxine medication to prevent problems, treatment must begin shortly after birth and is lifelong.</td>
</tr>
<tr>
<td>Emergency Medical Treatment</td>
<td>See sheet from American College of Medical Genetics (attached) or for more information, go to website: <a href="http://www.acmg.net/resources/policies/ACT/NB-Screen-Act-Sheet-Primary-TSH-4-28-06_ljo.pdf">http://www.acmg.net/resources/policies/ACT/NB-Screen-Act-Sheet-Primary-TSH-4-28-06_ljo.pdf</a></td>
</tr>
<tr>
<td>Inheritance</td>
<td>Although this disorder is detectable at birth, it is not an inherited disorder. Hypothyroidism does not follow any type of pattern as to whom it will affect and randomly affects infants from almost every origin.</td>
</tr>
<tr>
<td>General population incidence</td>
<td>Estimated to affect 1 in 4,500 births</td>
</tr>
<tr>
<td>Genetests Link</td>
<td><a href="http://www.genetests.org">www.genetests.org</a></td>
</tr>
<tr>
<td>Support Group</td>
<td>MAGIC Foundation for Children’s growth (MAGIC) <a href="http://www.magicfoundation.org">http://www.magicfoundation.org</a></td>
</tr>
<tr>
<td></td>
<td>National Organization for Rare Diseases <a href="http://www.rarediseases.org">http://www.rarediseases.org</a></td>
</tr>
<tr>
<td>Disease Name</td>
<td>Cystic Fibrosis</td>
</tr>
<tr>
<td>-------------------</td>
<td>------------------------------------------------------</td>
</tr>
<tr>
<td>Acronym</td>
<td>CF</td>
</tr>
<tr>
<td>Disease Classification</td>
<td>Genetic Disorder</td>
</tr>
</tbody>
</table>

Formerly known as cystic fibrosis of the pancreas, this entity has increasingly been labeled simply 'cystic fibrosis.' Manifestations relate not only to the disruption of exocrine function of the pancreas but also to intestinal glands (meconium ileus), biliary tree (biliary cirrhosis), bronchial glands (chronic bronchopulmonary infection with emphysema), and sweat glands (high sweat electrolyte with depletion in a hot environment). Infertility occurs in males and females.

**Symptom onset**

Usually within the first year of life. A small number, however, are not diagnosed until age 18 or older. These patients usually have a milder form of the disease.

**Symptoms**

Infants with CF have a variety of symptoms including: meconium ileus, liver disease, pancreatic insufficiency, pulmonary disease or an excessive appetite but poor weight gain; and greasy, bulky stools. Symptoms vary from person to person due, in part, to the more than 1,000 mutations of the CF gene. The sweat test is the standard diagnostic test for CF. A sweat test should be performed at a CF Foundation-accredited care center where strict guidelines are followed to ensure accurate results. This simple and painless procedure measures the amount of salt in the sweat. A high salt level indicates CF.

**Treatment**

The treatment of CF depends upon the stage of the disease and the organs involved. Clearing mucus from the lungs is an important part of the daily CF treatment regimen. In addition, approximately 90 percent of all people with CF take pancreatic enzyme supplements to help them absorb food in digestion.

**Emergency Medical Treatment**

See sheet from American College of Medical Genetics (attached) or for more information, go to website:
http://www.acmg.net/resources/policies/ACT/Act_Sheet-CF_4-17-06.pdf

**Inheritance**

Autosomal recessive

**General population incidence**

1 in 2,500 white live births and 1 in 17,000 African American live births.

**OMIM Link**


**Genetests Link**

www.genetests.org

**Support Group**

Cystic Fibrosis Foundation
http://www.cff.org/home

National Organization for Rare Diseases
http://www.rarediseases.org

9/15/06 Update
### Disease Name
Galactosemia

<table>
<thead>
<tr>
<th><strong>Acronym</strong></th>
<th>GALT</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Disease Classification</strong></td>
<td>Disorder of carbohydrate metabolism</td>
</tr>
<tr>
<td><strong>Variants</strong></td>
<td>Yes</td>
</tr>
<tr>
<td><strong>Variant name</strong></td>
<td>Duarte galactosemia</td>
</tr>
<tr>
<td><strong>Symptom onset</strong></td>
<td>Infancy</td>
</tr>
</tbody>
</table>

#### Symptoms
The affected infant may appear normal at birth. Within a few days to two weeks after initiating milk feedings, the infant develops vomiting, diarrhea, lethargy, jaundice, and liver damage. Untreated, the disorder may result in death, frequently associated with E. coli septicemia. Infants surviving the above symptoms may evidence developmental retardation, hepatomegaly, Fanconi's syndrome, growth failure and cataracts.

#### Natural history without treatment
If not detected immediately, it results in liver disease, cataracts, mental retardation, and even death. Death can occur as early as one to two weeks of age from severe escherichia (E. coli) bacteria infections. E. coli infections are common in untreated galactosemic infants. The American Liver Foundation recommends that all infants who develop jaundice be considered for galactosemia.

#### Natural history with treatment
As Galactosemic children get older they may encounter delays in speech and females may suffer from ovarian failure. Nevertheless, children who are diagnosed early have very good long-term outlooks and will lead normal, healthy lives.

#### Treatment
Treatment for galactosemia is the elimination of galactose and lactose from the diet throughout life. Infants are places on soy formula.

#### Emergency Medical Treatment
See sheet from American College of Medical Genetics (attached) or for more information, go to website: http://www.acmg.net/resources/policies/ACT/Act-Sheet-Galactose+GALT_4-28-06_ljo.pdf

#### Physical phenotype
No abnormalities present at birth.

#### Inheritance
Autosomal recessive

#### General population incidence
1:65,000 live births

#### OMIM Link

#### Genetests Link
www.geneclinics.org

#### Support Group

Children's Liver Alliance http://www.liverkids.org.au

Children Living with Inherited Metabolic Diseases http://www.climb.org.uk/
**Disease Name**

Glutaric acidemia, type 1

**Alternate name(s)**

Glutaric aciduria I, Glutaryl-CoA dehydrogenase deficiency

**Acronym**

GA1, GAI

**Disease Classification**

Organic Acid Disorder

**Variants**

Yes

**Variant name**

Riboflavin responsive GA1

**Symptom onset**

Infancy (typically 2-37 months)

**Symptoms**

Macrocephaly may be present at birth, acute encephalitic-like crises; neurodegenerative disorder with spasticity, dystonia, choreoathetosis, ataxia and dyskinesia, seizures, hypotonia, death due to Reye-like syndrome.

**Natural history without treatment**

Possible developmental delay due to encephalitis-like crisis; neurologic deterioration including spasticity, dystonic cerebral palsy. May have neurologic signs with normal IQ. Some individuals may be asymptomatic.

**Natural history with treatment**

If instituted before any damage occurs, normal outcome may occur. Risk for neurologic damage is highest in first few years. Some evidence that treatment may slow neurologic deterioration.

**Treatment**

Lysine and tryptophan restricted diet, riboflavin supplementation, carnitine supplementation. Rapid treatment of intercurrent illness with intravenous glucose, carnitine and appropriate supportive measures.

**Emergency Medical Treatment**

See sheet from American College of Medical Genetics (attached) or for more information, go to website: http://www.acmg.net/resources/policies/ACT/ACT-sheet_C5-DC_5-3-06_ljo.pdf

**Other**

Profuse sweating has been reported. Neuroradiographic findings of frontotemporal atrophy on CT or MRI with increased CSF containing spaces in the sylvian fissures and anterior to the temporal lobes. Also decreased attenuation in cerebral white matter on CT and increased signal intensity on MRI. Basal ganglia changes.

**Physical phenotype**

Macrocephaly, cerebral palsy

**Inheritance**

Autosomal recessive

**General population incidence**

1:40,000 in Caucasians and 1:30,000 in Sweden

**Ethnic differences**

Yes

**Population**

Old Amish and Ojibway Indians in Canada

**Ethnic incidence**

1/10 carrier frequency

**Enzyme location**

Mitochondria; liver, kidney, fibroblasts and leukocytes

**Enzyme Function**

Metabolizes lysine, hydroxylysine and tryptophan

**Missing Enzyme**

Glutaryl-CoA dehydrogenase

**Metabolite changes**

Increased glutaric acid in urine, increased glutaric acid and 3-hydroxyglutaric acid in plasma, 3-hydroxyglutaric and glutaconic acid in urine.

**Prenatal testing**

Enzyme activity in CVS and amniocytes

**MS/MS Profile**

Elevated C5DC - can be missed some patients

**OMIM Link**


**Genetests Link**

www.genetests.org

**Support Group**

Organic Acidemia Association

www.oaanews.org

Save Babies through Screening Foundation

www.savebabies.org

Genetic Alliance

www.geneticalliance.org
### Health Care Provider Fact Sheet

<table>
<thead>
<tr>
<th>Disease Name</th>
<th>Hemoglobin S-β Thalassemia Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alternate Name(s)</td>
<td>Beta Thalassemia Sickle Disease</td>
</tr>
<tr>
<td>Acronym</td>
<td>Hb β/S</td>
</tr>
<tr>
<td>Disease Classification</td>
<td>Hemoglobinopathy</td>
</tr>
</tbody>
</table>

Infants whose hemoglobin does not produce enough beta protein have beta thalassemia. It is found in people of Mediterranean descent, such as Italians and Greeks, and is also found in the Arabian Peninsula, Iran, Africa, Southeast Asia and southern China. There are three types of beta thalassemia that also range from mild to severe in their effect on the body.

#### Thalassemia Minor or Thalassemia Trait
In this condition, the lack of beta protein is not great enough to cause problems in the normal functioning of the hemoglobin. A person with this condition simply carries the genetic trait for thalassemia and will usually experience no health problems other than a possible mild anemia.

#### Thalassemia Intermedia
In this condition, the lack of beta protein in the hemoglobin is great enough to cause a moderately severe anemia and significant health problems, including bone deformities and enlargement of the spleen. However, there is a wide range in the clinical severity of this condition, and the borderline between thalassemia intermedia and the most severe form, thalassemia major, can be confusing. The deciding factor seems to be the amount of blood transfusions required by the patient. The more dependent the patient is on blood transfusions, the more likely he or she is to be classified as thalassemia major. Generally speaking, patients with thalassemia intermedia need blood transfusions to improve their quality of life, but not in order to survive.

#### Thalassemia Major or Cooley’s Anemia
This is the most severe form of beta thalassemia in which the complete lack of beta protein in the hemoglobin causes a life-threatening anemia that requires regular blood transfusions and extensive ongoing medical care. These extensive, lifelong blood transfusions lead to iron-overload which must be treated with chelation therapy to prevent early death from organ failure.

### Symptoms
Most children with thalassemia major appear healthy at birth, but during the first year or two of life they become pale, listless and fussy, and have a poor appetite. They grow slowly and often develop jaundice (yellowing of the skin). The spleen, liver, and heart soon become greatly enlarged. Bones become thin and brittle; face bones become distorted, and children with thalassemia often look alike. Heart failure and infection are the leading causes of death among children with untreated thalassemia major. Children with thalassemia intermedia may develop some of the same complications, although in most cases, the course of the disease is mild for the first two decades of life.

### Treatment
**Red Blood Cell Transfusion**
Because there is no natural way for the body to eliminate iron, the iron in the transfused blood cells builds up in a condition known as “iron overload” and becomes toxic to tissues and organs, particularly the liver and heart. Iron overload typically results in the patient's early death from organ failure.

**Chelation Therapy:** To help remove excess iron, patients undergo the difficult and painful infusion of a drug, Desferal. Reduced mortality and morbidity with appropriate penicillin prophylaxis.

### Emergency Medical Treatment
See sheet from American College of Medical Genetics (attached) or for more information, go to website:
http://www.acmg.net/resources/policies/T_THALASIEMIA_S_BETA plusgethermfasa_4-28-06.pdf

### Inheritance
Autosomal recessive

### General population incidence
1:250,000

### Genetests Link
[www.geneclinics.org](http://www.geneclinics.org)

### Support Group
- Cooley's Anemia Foundation
  - [http://www.cooleysanemia.org/](http://www.cooleysanemia.org/)
- Sickle Cell Information Center
- Sickle Cell Disease Association of America, Inc.
  - [http://www.sicklecelldisease.org](http://www.sicklecelldisease.org)

---

9/15/06 Update
<table>
<thead>
<tr>
<th><strong>Disease Name</strong></th>
<th>Hemoglobin S/C Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Alternate Name(s)</strong></td>
<td>Sickle Cell Hemoglobin C Disease</td>
</tr>
<tr>
<td><strong>Acronym</strong></td>
<td>Hb S/C</td>
</tr>
<tr>
<td><strong>Disease Classification</strong></td>
<td>Hemoglobinopathy</td>
</tr>
<tr>
<td><strong>Symptom onset</strong></td>
<td>May be asymptomatic.</td>
</tr>
<tr>
<td><strong>Symptoms</strong></td>
<td>Any sign of illness in an infant with sickling disease is a potential medical emergency. Acute and chronic tissue injury can occur when sickled cells cause vascular occlusion. Sickling diseases can cause severe pain anywhere in the body, but most often in the hands, arms, chest, legs and feet. Complications may include, but are not limited to, the following: sepsis, acute chest syndrome, hand-and-foot syndrome, splenic sequestration crisis, aplastic crisis, stroke and painful episodes.</td>
</tr>
<tr>
<td><strong>Natural history without treatment</strong></td>
<td>Infants with hemoglobin C disease are vulnerable to serious bacterial infections that can be life threatening.</td>
</tr>
<tr>
<td><strong>Natural history with treatment</strong></td>
<td>Reduced mortality and morbidity with penicillin prophylaxis.</td>
</tr>
<tr>
<td><strong>Treatment</strong></td>
<td>The National Institutes of Health clinical guidelines for management of sickle cell disease state, &quot;Penicillin prophylaxis should begin by 2 months of age for infants with suspected sickle cell anemia, whether or not the definitive diagnosis has been established.&quot; Antibiotic therapy should continue until at least 5 years of age.</td>
</tr>
<tr>
<td><strong>Emergency Medical Treatment</strong></td>
<td>See sheet from American College of Medical Genetics (attached) or for more information, go to website: <a href="http://www.acmg.net/resources/policies/ACT/ACT_sheet_HBSS_FS_4-28-06-ljo.pdf">http://www.acmg.net/resources/policies/ACT/ACT_sheet_HBSS_FS_4-28-06-ljo.pdf</a></td>
</tr>
<tr>
<td><strong>Inheritance</strong></td>
<td>Autosomal recessive</td>
</tr>
<tr>
<td><strong>General population incidence</strong></td>
<td>Affects 2 to 3% of African American in the United States.</td>
</tr>
<tr>
<td><strong>Genetests Link</strong></td>
<td><a href="http://www.geneclinics.org">www.geneclinics.org</a></td>
</tr>
<tr>
<td><strong>Support Group</strong></td>
<td>Sickle Cell Information Center <a href="http://www.scinfo.org/">http://www.scinfo.org/</a></td>
</tr>
<tr>
<td></td>
<td>Sickle Cell Disease Association of America, Inc. <a href="http://www.sicklecelldisease.org">http://www.sicklecelldisease.org</a></td>
</tr>
<tr>
<td><strong>Disease Name</strong></td>
<td>Homocystinuria</td>
</tr>
<tr>
<td>---------------------</td>
<td>----------------</td>
</tr>
<tr>
<td><strong>Alternate name(s)</strong></td>
<td>Cystathionine beta-synthase deficiency</td>
</tr>
<tr>
<td><strong>Acronym</strong></td>
<td>CBS deficiency</td>
</tr>
<tr>
<td><strong>Disease Classification</strong></td>
<td>Amino Acid Disorder</td>
</tr>
<tr>
<td><strong>Variants</strong></td>
<td>Yes</td>
</tr>
<tr>
<td><strong>Variant name</strong></td>
<td>Pyridoxine-responsive type (the majority of cases are unresponsive to pyridoxine)</td>
</tr>
<tr>
<td><strong>Symptom onset</strong></td>
<td>Childhood</td>
</tr>
<tr>
<td><strong>Symptoms</strong></td>
<td>Ectopia lentis, vascular occlusive disease, seizures, malar flush, osteoporosis, possible decreased pigmentation of hair, skin and iris, skeletal abnormalities including genu valgum, pectus excavatum, pes cavus and marfanoid habitus. Some patients have failure to thrive and short stature. Mental retardation is possible.</td>
</tr>
<tr>
<td><strong>Natural history without treatment</strong></td>
<td>Mental retardation is common but not invariable. Vascular disease, stroke and psychiatric abnormalities.</td>
</tr>
<tr>
<td><strong>Natural history with treatment</strong></td>
<td>Decrease of thromboembolic accidents which may decrease incidence of sequelae including mental retardation, ectopia lentis, seizures and psychiatric abnormalities. Normal IQ is possible and typical of the pyridoxine-responsive variant.</td>
</tr>
<tr>
<td><strong>Treatment</strong></td>
<td>Pyridoxine supplementation, dietary restriction of methionine with supplementation of L-cysteine, betaine supplementation. Consider folate and vitamin B12 supplementation.</td>
</tr>
<tr>
<td><strong>Emergency Medical Treatment</strong></td>
<td>See sheet from American College of Medical Genetics (attached) or for more information, go to website: <a href="http://www.acmg.net/resources/policies/ACT/Act-Sheet-Methionine_5-2-06_ljo.pdf">http://www.acmg.net/resources/policies/ACT/Act-Sheet-Methionine_5-2-06_ljo.pdf</a></td>
</tr>
<tr>
<td><strong>Physical phenotype</strong></td>
<td>Ectopia lentis, decreased pigmentation, malar flush, osteoporosis, skeletal abnormalities and marfanoid habitus</td>
</tr>
<tr>
<td><strong>Inheritance</strong></td>
<td>Autosomal recessive</td>
</tr>
<tr>
<td><strong>General population incidence</strong></td>
<td>1:200,000 – 300,000</td>
</tr>
<tr>
<td><strong>Ethnic differences</strong></td>
<td>Yes</td>
</tr>
<tr>
<td><strong>Population</strong></td>
<td>Irish, U.S New England</td>
</tr>
<tr>
<td><strong>Ethnic incidence</strong></td>
<td>1:50,000</td>
</tr>
<tr>
<td><strong>Enzyme location</strong></td>
<td>Lymphocytes, fibroblasts and liver</td>
</tr>
<tr>
<td><strong>Enzyme Function</strong></td>
<td>Degradation of homocysteine</td>
</tr>
<tr>
<td><strong>Missing Enzyme</strong></td>
<td>Cystathionine beta-synthase</td>
</tr>
<tr>
<td><strong>Metabolite changes</strong></td>
<td>Increased methionine in blood, increased homocystine in urine, increased total homocysteine in blood.</td>
</tr>
<tr>
<td><strong>Prenatal testing</strong></td>
<td>Enzyme assay in cultured amniocytes (CVS not possible)</td>
</tr>
<tr>
<td><strong>Genetests Link</strong></td>
<td><a href="http://www.genetests.org">www.genetests.org</a></td>
</tr>
<tr>
<td><strong>Support Group</strong></td>
<td>National Coalition for PKU and Allied Disorders <a href="http://www.pku-allieddisorders.org/">http://www.pku-allieddisorders.org/</a> Children Living with Inherited Metabolic Diseases <a href="http://www.climb.org.uk/">http://www.climb.org.uk/</a></td>
</tr>
</tbody>
</table>
Disease Name | Hydroxymethylglutaric aciduria (3-OH 3-CH3 glutaric aciduria)
---|---
Alternate name(s) | Methylglutaric aciduria (3-hydroxy-3-methylglutaryl-CoA lyase deficiency)
Acronym | HMG-CoA lyase deficiency
Disease Classification | Organic Acid Disorder
Variants | No
Variant name | N/A
Symptom onset | Infancy (6 months to 2 years)
Symptoms | Persistent vomiting, lethargy, hypotonia, coma, seizures, apnea, hepatomegaly.
Natural history without treatment | Recurrent episodes of acute illness usually in response to fasting or to viral infection. Any episode can lead to death or developmental delay if severe enough.
Natural history with treatment | Normal IQ and development are possible. Severe hypoglycemic episodes may result in seizures and mental retardation.
Emergency Medical Treatment | See sheet from American College of Medical Genetics (attached) or for more information, go to website: http://www.acmg.net/resources/policies/ACT/ACT-sheet_C5-OH_4-29-06.pdf
Other | Crises consist of severe acidosis and hypoglycemia treated with IV glucose and bicarbonate administration.
Physical phenotype | Possible microcephaly
Inheritance | Autosomal recessive
General population incidence | Rare
Ethnic differences | No
Population | N/A
Ethnic incidence | N/A
Enzyme location | Liver, fibroblasts and leukocytes
Enzyme Function | Catalyzes the final step of leucine degradation and plays a role in ketone formation.
Missing Enzyme | HMG CoA lyase
Metabolite changes | 3-hydroxy-3-methylglutaric acid in urine, increased levels of glutaric and adipic acids may be elevated in urine during crisis, notable absence of ketosis.
Prenatal testing | Prenatal testing has been accomplished by analysis of metabolites in maternal urine at 23 weeks. Enzyme is active in amniocytes and prenatal testing should be possible using this method.
MS/MS Profile | N/A
Genetests Link | www.genetests.org
Support Group | Organic Acidemia Association
| www.oaanews.org
| Save Babies through Screening Foundation
| www.savebabies.org
| Genetic Alliance
| www.geneticalliance.org
**Health Care Provider Fact Sheet**

**Disease Name**: Isovaleric acidemia

**Alternate name(s)**: Isovaleric acid CoA dehydrogenase deficiency

**Acronym**: IVA

**Disease Classification**: Organic Acid Disorder

**Variants**: Yes

**Variant name**: Chronic intermittent form

**Symptom onset**: Infancy (in the acute neonatal form). The chronic intermittent form presents later in infancy or in childhood.

**Symptoms**: Episodic overwhelming illness with vomiting, ketosis, acidosis and coma. Hematological abnormalities include leucopenia, thrombocytopenia and possible anemia.

**Natural history without treatment**: About 50% of patients with the acute neonatal form will die during their first episode. Survivors may have neurological damage though several have made complete recoveries. Patients with the chronic form may have neurologic damage, but the majority of patients are developmentally normal.

**Natural history with treatment**: Intellectual prognosis depends on early diagnosis and treatment and subsequently on long-term compliance. If treated appropriately, most will have normal development.

**Treatment**: Low protein diet with restricted leucine intake, glycine supplementation and possible carnitine supplementation.

**Emergency Medical Treatment**: See sheet from American College of Medical Genetics (attached) or for more information, go to website: http://www.acmg.net/resources/policies/ACT/ACT-sheet_C5_5-3-06.pdf Sometimes a “sweaty feet” odor is reported during an acute crisis.

**Other**: No obvious dysmorphic features.

**Inheritance**: Autosomal recessive

**General population incidence**: 1:230,000

**Ethnic differences**: None known

**Population**: N/A

**Ethnic incidence**: N/A

**Enzyme location**: N/A

**Enzyme Function**: Isovaleryl-CoA dehydrogenase is the first step in the branched chain organic acid metabolism of leucine.

**Missing Enzyme**: Isovaleryl-CoA dehydrogenase

**Metabolite changes**: Urinary isovaleryl glycinne, 3-hydroxysoraline acid, increased isovaleric acid in blood. During acute attacks, 4-hydroxyisovaleric acid, mesaconic acid, and methylsuccinic acid, isovalerylglycine and 3-hydroxyisovaleric acid are present.

**Prenatal testing**: Enzyme analysis by GCMS in amniotic fluid or CVS tissue.

**MS/MS Profile**: Elevated C5 isovaleryl carnitine


**Genetests Link**: www.genetests.org

**Support Link**: Organic Acidemia Association www.oaanews.org

**Support Group**: Save Babies through Screening Foundation www.savebabies.org

**Support Group**: Genetic Alliance www.geneticalliance.org

9/15/06 Update -8AE-
<table>
<thead>
<tr>
<th><strong>Disease Name</strong></th>
<th>Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Alternate name(s)</strong></td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Acronym</strong></td>
<td>LCHADD/TFP</td>
</tr>
<tr>
<td><strong>Disease Classification</strong></td>
<td>Fatty Acid Oxidation Disorder</td>
</tr>
<tr>
<td><strong>Variants</strong></td>
<td>Yes</td>
</tr>
<tr>
<td><strong>Variant name</strong></td>
<td>Mitochondrial trifunctional protein deficiency</td>
</tr>
<tr>
<td><strong>Symptom onset</strong></td>
<td>Neonatal, infancy</td>
</tr>
<tr>
<td><strong>Symptoms</strong></td>
<td>Hypoketotic hypoglycemia, hypotonia, cardiomyopathy, hepatic disease, peripheral neuropathy and pigmentary retinopathy, rhabdomyolysis, sudden death</td>
</tr>
<tr>
<td><strong>Natural history without treatment</strong></td>
<td>Possible developmental delay due to damage from hypoglycemic episodes, possible death due to cardiomyopathy or hepatic failure.</td>
</tr>
<tr>
<td><strong>Natural history with treatment</strong></td>
<td>Intelligence is usually normal if there is no damage due to hypoglycemic crisis. Peripheral neuropathy, if present, may not improve with treatment.</td>
</tr>
<tr>
<td><strong>Treatment</strong></td>
<td>Avoidance of fasting, use of uncooked starch, MCT treatments, carnitine supplementation, DHA supplementation (may prevent retinopathy, but this has not been proven)</td>
</tr>
<tr>
<td><strong>Emergency Medical Treatment</strong></td>
<td>See sheet from American College of Medical Genetics (attached) or for more information, go to website: <a href="http://www.acmg.net/resources/policies/ACT/ACT_sheet_C16-OH_5_3_06.pdf">http://www.acmg.net/resources/policies/ACT/ACT_sheet_C16-OH_5_3_06.pdf</a></td>
</tr>
<tr>
<td><strong>Other</strong></td>
<td>Maternal complications in pregnancy include acute fatty liver of pregnancy, HELLP syndrome, and pre-eclampsia</td>
</tr>
<tr>
<td><strong>Physical phenotype</strong></td>
<td>Hypotonia, cardiomyopathy and possible retinal changes</td>
</tr>
<tr>
<td><strong>Inheritance</strong></td>
<td>Autosomal recessive</td>
</tr>
<tr>
<td><strong>General population incidence</strong></td>
<td>Rare</td>
</tr>
<tr>
<td><strong>Ethnic differences</strong></td>
<td>Yes</td>
</tr>
<tr>
<td><strong>Population</strong></td>
<td>Finnish</td>
</tr>
<tr>
<td><strong>Ethnic incidence</strong></td>
<td>1:240 carrier rate for common mutation G1528C in Finland</td>
</tr>
<tr>
<td><strong>Enzyme location</strong></td>
<td>Inner mitochondrial membrane, liver, heart, fibroblasts</td>
</tr>
<tr>
<td><strong>Enzyme Function</strong></td>
<td>Metabolizes long chain fatty acids (C-12 to C-16 in length)</td>
</tr>
<tr>
<td><strong>Missing Enzyme</strong></td>
<td>Long-chain 3-hydroxyacyl-CoA dehydrogenase or mitochondrial trifunctional protein</td>
</tr>
<tr>
<td><strong>Metabolite changes</strong></td>
<td>Increased 3-hydroxydicarboxylic acids in urine, increased saturated and unsaturated 3-hydroxy organic acids, possible elevated CPK during acute illness.</td>
</tr>
<tr>
<td><strong>Prenatal testing</strong></td>
<td>Enzyme analysis, protein analysis and direct DNA (when applicable).</td>
</tr>
<tr>
<td><strong>MS/MS Profile</strong></td>
<td>C18:OH, C16:1OH, C16OH</td>
</tr>
<tr>
<td><strong>Genetests Link</strong></td>
<td><a href="http://www.genetests.org">www.genetests.org</a></td>
</tr>
</tbody>
</table>
## Health Care Provider Fact Sheet

<table>
<thead>
<tr>
<th>Disease Name</th>
<th>Maple syrup urine disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alternate name(s)</td>
<td>Branched chain ketoaciduria, Branched chain alpha-keto dehydrogenase deficiency</td>
</tr>
<tr>
<td>Acronym</td>
<td>MSUD type 1A, BCKD deficiency</td>
</tr>
<tr>
<td>Disease Classification</td>
<td>Amino Acid Disorder</td>
</tr>
<tr>
<td>Variants</td>
<td>Yes</td>
</tr>
<tr>
<td>Variant name</td>
<td>MSUD type 1B, MSUD Type II, Intermittent branched-chain ketoaciduria, Intermediate branched-chain ketoaciduria, Thiamine responsive MSUD</td>
</tr>
<tr>
<td>Symptom onset</td>
<td>Neonatal with some variability</td>
</tr>
<tr>
<td>Symptoms</td>
<td>Lethargy progressive to coma and possible death, vomiting, difficulty feeding, opisthotonic posturing, hypoglycemia, possible high pitched cry.</td>
</tr>
<tr>
<td>Natural history without treatment</td>
<td>Neurologic abnormalities and profound mental retardation.</td>
</tr>
<tr>
<td>Natural history with treatment</td>
<td>Normal IQ and development may be expected if treatment is initiated before first crisis, but development is delayed in the severest cases.</td>
</tr>
<tr>
<td>Treatment</td>
<td>Dietary restriction of the branched chain amino acids and supplementation with medical formula. Thiamine supplementation in thiamine responsive patients.</td>
</tr>
<tr>
<td>Other</td>
<td>“Maple syrup”-like odor to urine (usually present during crisis)</td>
</tr>
<tr>
<td>Emergency Medical Treatment</td>
<td>See sheet from American College of Medical Genetics (attached) or for more information, go to website: <a href="http://www.acmg.net/resources/policies/ACT/Act-Sheet-Leucine_5-2-06_ljo.pdf">http://www.acmg.net/resources/policies/ACT/Act-Sheet-Leucine_5-2-06_ljo.pdf</a></td>
</tr>
<tr>
<td>Physical phenotype</td>
<td>None</td>
</tr>
<tr>
<td>Inheritance</td>
<td>Autosomal recessive</td>
</tr>
<tr>
<td>General population incidence</td>
<td>1:200,000</td>
</tr>
<tr>
<td>Ethnic differences</td>
<td>Yes</td>
</tr>
<tr>
<td>Population</td>
<td>Mennonites, French-Canadians</td>
</tr>
<tr>
<td>Ethnic incidence</td>
<td>1/760 (Mennonites)</td>
</tr>
<tr>
<td>Enzyme location</td>
<td>Inner mitochondrial membrane; liver, kidney, leukocytes and fibroblasts.</td>
</tr>
<tr>
<td>Enzyme Function</td>
<td>Catalyzes the decarboxylation of o xoacids.</td>
</tr>
<tr>
<td>Missing Enzyme</td>
<td>Branched-chain ketoacid dehydrogenase (BCKAD). This enzyme is a multienzyme complex with 3 components – E1, E2 and E3.</td>
</tr>
<tr>
<td>Metabolite changes</td>
<td>Increased leucine, isoleucine and valine in plasma and urine, increased organic acids in urine.</td>
</tr>
<tr>
<td>Prenatal testing</td>
<td>Enzyme testing by CVS or amnio. If mutation is known, DNA testing may be available.</td>
</tr>
<tr>
<td>MS/MS Profile</td>
<td>Leucine elevated, leucine to alanine ratio elevated.</td>
</tr>
<tr>
<td>Genetests Link</td>
<td><a href="http://www.genetests.org">www.genetests.org</a></td>
</tr>
</tbody>
</table>
## Health Care Provider Fact Sheet

**Medium-chain acyl-CoA dehydrogenase deficiency**

<table>
<thead>
<tr>
<th>Disease Name</th>
<th>Medium-chain acyl-CoA dehydrogenase deficiency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alternate name(s)</td>
<td>None</td>
</tr>
<tr>
<td>Acronym</td>
<td>MCADD</td>
</tr>
<tr>
<td>Disease Classification</td>
<td>Fatty Acid Oxidation Disorder</td>
</tr>
<tr>
<td>Variants</td>
<td>N/A</td>
</tr>
<tr>
<td>Variant name</td>
<td>N/A</td>
</tr>
<tr>
<td>Symptom onset</td>
<td>Typically 6-24 months but ranges from neonatal to adult</td>
</tr>
<tr>
<td>Symptoms</td>
<td>Recurrent episodes of hypoglycemia, vomiting, coma, sudden death and possible seizures. Hepatomegaly usually present.</td>
</tr>
<tr>
<td>Natural history without treatment</td>
<td>Metabolic episodes can cause developmental and physical delays, neurologic impairment and sudden death.</td>
</tr>
<tr>
<td>Natural history with treatment</td>
<td>Normal intellect and physical functioning expected.</td>
</tr>
<tr>
<td>Treatment</td>
<td>Dietary: avoid fasting, low-fat diet (&lt;30% of dietary fat), carnitine supplementation, cornstarch supplementation.</td>
</tr>
<tr>
<td>Emergency Medical Treatment</td>
<td>See sheet from American College of Medical Genetics (attached) or for more information, go to website: <a href="http://www.acmg.net/resources/policies/ACT/ACT_sheet_C8_C6">http://www.acmg.net/resources/policies/ACT/ACT_sheet_C8_C6</a> andC10_05-03-06_ljo.pdf</td>
</tr>
<tr>
<td>Physical phenotype</td>
<td>None</td>
</tr>
<tr>
<td>Inheritance</td>
<td>Autosomal recessive</td>
</tr>
<tr>
<td>General population incidence</td>
<td>1/15,000</td>
</tr>
<tr>
<td>Ethnic differences</td>
<td>Yes</td>
</tr>
<tr>
<td>Population</td>
<td>Incidence higher in Northern Europeans and U.S Caucasians.</td>
</tr>
<tr>
<td>Ethnic incidence</td>
<td>Approximately 1/70 carrier rate</td>
</tr>
<tr>
<td>Enzyme location</td>
<td>Liver, heart, muscle and fibroblasts</td>
</tr>
<tr>
<td>Enzyme Function</td>
<td>Mitochondrial beta-oxidation of fat stores</td>
</tr>
<tr>
<td>Missing Enzyme</td>
<td>Medium-chain acyl-CoA dehydrogenase</td>
</tr>
<tr>
<td>Metabolite changes</td>
<td>Increased medium chain fatty acids, increased glycine/carnitine esters, increased dicarboxylic acids.</td>
</tr>
<tr>
<td>Prenatal testing</td>
<td>DNA and enzymatic testing</td>
</tr>
<tr>
<td>MS/MS Profile</td>
<td>Elevated C10:1, C8, C6</td>
</tr>
<tr>
<td>Genetests Link</td>
<td><a href="http://www.genetests.org">www.genetests.org</a></td>
</tr>
<tr>
<td>Support Group</td>
<td>FOD Family Support Group</td>
</tr>
<tr>
<td></td>
<td><a href="http://www.fodsupport.org">http://www.fodsupport.org</a></td>
</tr>
<tr>
<td></td>
<td>Organic Acidemia Association</td>
</tr>
<tr>
<td></td>
<td><a href="http://www.oaanews.org">Http://www.oaanews.org</a></td>
</tr>
<tr>
<td></td>
<td>Save Babies through Screening Foundation</td>
</tr>
<tr>
<td></td>
<td><a href="http://www.savebabies.org">http://www.savebabies.org</a></td>
</tr>
<tr>
<td></td>
<td>Genetic Alliance</td>
</tr>
<tr>
<td></td>
<td><a href="http://www.geneticalliance.org">http://www.geneticalliance.org</a></td>
</tr>
</tbody>
</table>

9/15/06 Update
## Disease Name

**Methylmalonic acidemia**

### Alternate name(s)
Methylmalonic acidemia, Vitamin B-12 responsive, due to defect in adenosylcobalamin, cblA complementation type; Methylmalonic acidemia, cblA type; Methylmalonic acidemia, Vitamin B-12 responsive, due to defect in synthesis of adenosylcobalamin, cbl B complementation type

### Acronym
MMA, MMAA/MMAB

### Disease Classification
Organic Acid Disorder

### Variants
Yes

### Variant name
Methylmalonic acidemia, Vitamin B-12 non-responsive; Combined deficiency of methylmalonyl-CoA mutase and homocysteine

### Symptom onset
Variable. Ranges from the first days of life to completely asymptomatic.

### Symptoms
Episodic ketoacidosis with vomiting accompanied by lethargy and coma which can lead to death. Survivors can have developmental delays, growth retardation, spastic quadriaparesis, dystonia and seizures. Neutropenia, thrombocytopenia and osteoporosis are common complications.

### Natural history without treatment
Variable depending on the enzyme defect. Some will die in the newborn period, others will survive with deficits and others will be asymptomatic.

### Natural history with treatment
**CblA:** Good prognosis with injections of hydroxy-cobalamin (OH-cbl) which reverses biochemical and clinical abnormalities in about 90% of patients.

**CblB:** Equal fractions of affected patients are alive and well, alive and impaired, or deceased. The age of onset of symptoms can help prognosticate outcome – those patients with a later onset of symptoms have a more benign course. Approximately 40% of patients will respond with a drop in MMA level when given OH-cbl injections.

### Treatment
Protein restricted diet, OH-cbl injections, carnitine supplementation, oral antibiotic therapy to decrease propionate and medical foods. Liver transplant or combined liver/kidney transplant may increase metabolic control, but may not prevent neurologic complications.

### Emergency Medical Treatment
See sheet from American College of Medical Genetics (attached) or for more information, go to website:
http://www.acmg.net/resources/policies/ACT/ACT-sheet-C3_5-3-06_jlo.pdf

### Physical phenotype
Minor facial dysmorphisms including high forehead, broad nasal bridge, epicanthal folds, long, smooth philtrum and triangular mouth. A variety of skin lesions can be seen in patients due to moniliasis.

### Inheritance
Autosomal recessive

### General population incidence
1:48,000

### Ethnic differences
No known population at increased risk

### Population
N/A

### Ethnic incidence
N/A

### Enzyme location
Mitochondria

### Enzyme Function
Production of adenosylcobalamin

### Missing Enzyme
Cobalamin A (cblA) deficiency: cobalamin reductase

### Metabolite changes
Elevated glycine in urine

### Prenatal testing
Possible via enzyme assay on amniocytes or CVS..

### MS/MS Profile
Elevated C3 propionyl carnitine, elevated C4 DC methylmalonyl carnitine.

### OMIM Link

### Genetests Link
www.genetests.org

### Support Group
Organic Acidemia Association
www.oaanews.org

Save Babies through Screening Foundation
www.savebabies.org

Genetic Alliance
www.geneticalliance.org

Fatty Oxidation Disorder (FOD) Family Support Group
www.fodsupport.org
Disease Name: Methylmalonic acidemia mutase deficiency
Alternate name(s): Methylmalonic aciduria due to methylmalonic CoA mutase deficiency, Complementation group mut0, Methylmalonyl-CoA mutase
Acronym: MMA
Disease Classification: Organic Acid Disorder
Variants: Yes
Variant name: Vitamin B12 metabolic defect with methylmalonic acidemia and homocystinuria
Symptom onset: Eighty percent of infants become ill during the first week or life and 90% will present by the end of the first month. Infants with the less severe mutation may present later than the first month. A few may remain asymptomatic or present much later in life depending on the residual enzyme activity and the metabolic stressors.
Symptoms: Most common signs and symptoms are lethargy, failure to thrive, recurrent vomiting, dehydration which leads to profound metabolic acidosis, respiratory distress, hypotonia and death if not recognized. Complications of acute episodes can include metabolic stroke, extrapyramidal signs, dystonia and bilateral lucencies of globus pallidus. Survivors may have significant neurological damage. Renal failure may appear during childhood. Clinical spectrum is wide, ranging from fatal neonatal disease to asymptomatic individuals. Patients do not have to have clinical crises in order to have neurological or other organ compromise.
Natural history without treatment: Variable depending on the enzyme defect and the patient. Some will die as a neonate, others will survive with deficits and a few others will remain asymptomatic.
Natural history with treatment: About 60% of patients die within the first year of life and of those that survive, 40% are distinctly developmentally impaired. Age of onset of symptoms can help prognosticate – those with later onset tend to have a more benign course. Liver and liver/kidney transplant are one treatment option. However, liver transplants have significant preoperative risk and there is documentation of neurological problems after transplant despite improved biochemical values. Renal transplants have shown good response with drops in methylmalonic acid levels, normalization of the diet and absence of acute episodes of metabolic decompensation. However, the effect of any type of transplant is limited because the MMA enzyme is in all tissues and the transplants do not affect the levels made in the cerebro-spinal fluid and brain.
Treatment: Protein restricted diet, OH-Cbl injections, carnitine supplementation and oral antibiotic therapy to decrease gut production of propionate. Special medical foods (formula) deficient in methionine, threonine, valine, isoleucine, odd chain fatty acids and cholesterol. Liver transplant and liver/kidney transplant.
Emergency Medical Treatment: See sheet from American College of Medical Genetics (attached) or for more information, go to website: http://www.acmg.net/resources/policies/ACT/ACT-sheet-C3_5-3-06_ljo.pdf
Physical phenotype: Most patients have no obvious dysmorphic features. Some patients, in whom there is known consanguinity, have had associated birth defects, congenital heart defects, hydronephrosis and facial dysmorphisms.
Inheritance: Autosomal recessive
General population incidence: 1:48,000
Ethnic differences: None known
Population: N/A
Ethnic incidence: N/A
Enzyme location: Liver, kidneys, cerebrospinal fluid, brain
Enzyme Function: Catalyzes methylmalonyl-CoA to succinyl-CoA
Missing Enzyme: Methylmalonyl-CoA mutase
Metabolite changes: Increased methylmalonic acid in blood and urine.
Prenatal testing: Possible via enzyme assay on amniocytes or CVS.
MS/MS Profile: Elevated C3 propionyl carnitine, elevated C4 DC methylmalonyl carnitine.
Genetests Link: www.genetests.org
Save Babies through Screening Foundation www.savebabies.org
Genetic Alliance www.geneticalliance.org
# Health Care Provider Fact Sheet

## Disease Name
Multiple Carboxylase Deficiency

## Alternate name(s)
- Holocarboxylase Synthetase Deficiency; Neonatal Form
- Holocarboxylase Deficiency

## Acronym
MCD

## Disease Classification
Organic Acid Disorder

## Variants
- Neonatal Form

## Variant name
Multiple Carboxylase Deficiency, Neonatal Form

## Symptom onset
Anytime from birth to 15 months of age.

## Symptoms
Infants generally present with food refusal, vomiting, breathing problems, hypotonia, seizures, and lethargy. Severe metabolic/lactic acidosis, organic aciduria, mild hyperammonemia and variable hypoglycemia can lead to coma and death if not treated. Survivors can have neurological damage. Patients may have skin rash and alopecia at later stages.

## Natural history without treatment
Repeated bouts of acidosis, skin rashes, failure to thrive, coma, developmental delay and death.

## Natural history with treatment
Children with holocarboxylase synthetase deficiency, treated with biotin have normal growth and development. However, some only partly respond to therapy and one has been reported to be unresponsive to biotin therapy.

## Treatment
Majority of cases respond readily to biotin supplementation. Biotin increases the functional activation of the carboxylase enzymes.

## Emergency Medical Treatment
See sheet from American College of Medical Genetics (attached) or for more information, go to website: [http://www.acmg.net/resources/policies/ACT/ACT-sheet_C5-OH_4-29-06.pdf](http://www.acmg.net/resources/policies/ACT/ACT-sheet_C5-OH_4-29-06.pdf)

## Physical phenotype
None

## Inheritance
Autosomal recessive

## General population incidence
1:87,000

## Ethnic differences
No known population at increased risk

## Missing Enzyme
Holocarboxylase synthetase (HS) attaches biotin to the four carboxylase enzymes (pyruvate carboxylase; propionyl CoA carboxylase; beta-methylcrotonyl CoA carboxylase; acetyl CoA carboxylase) in order to activate them. Deficiency of HS results in functional deficiencies of all the carboxylase enzymes.

## MS/MS Profile
- C3 (propionyl carnitine) – elevated
- C5-OH (3-hydroxyisovaleryl carnitine) - elevated

## OMIM Link

## Genetests Link
[www.genetests.org](http://www.genetests.org)

## Support Group
- Organic Acidemia Association
  [www.oaanews.org](http://www.oaanews.org)
- Save Babies through Screening Foundation
  [www.savebabies.org](http://www.savebabies.org)
- Genetic Alliance
  [www.geneticalliance.org](http://www.geneticalliance.org)

9/15/06 Update

-8AQ-
**Disease Name**  
Phenylketonuria

**Alternate name(s)**  
Hyperphenylalaninemia, Phenylalanine hydroxylase deficiency, Følling disease

**Acronym**  
PKU

**Disease Classification**  
Amino Acid Disorder

**Variants**  
Yes

**Variant name**  
Benign phenylketonuria, Mild phenylketonuria, Variant phenylketonuria, Bioterin-responsive phenylketonuria  
Tetrahydrobiopterin deficiencies:  
GTP cyclohydrolase I deficiency, 6-Pyruvoyl-tetrahydropterin synthase deficiency, Dihydropteridine reductase deficiency, Pterin-4-carbinolamine dehydratase deficiency

**Symptom onset**  
Infancy

**Symptoms**  
Mental retardation, decreased pigmentation relative to family members, eczematous rash, seizures, abnormal gait, and unusual "mousy" odor to urine.

**Natural history without treatment**  
Mental retardation in the moderate to severe range, hyperactivity, eczema, mild neurologic manifestations, possible abnormal gait microcephaly.

**Natural history with treatment**  
If diet instituted early, normal IQ and development can be expected.

**Treatment**  
Dietary restriction of phenylalanine with supplementary formula for tyrosine and essential amino acids.

**Other**  
"Mousy" or "musky" smelling urine. Females with PKU are at-risk to have children affected by maternal PKU (increased levels of phenylalanine are teratogenic).

**Emergency Medical Treatment**  
See sheet from American College of Medical Genetics (attached) or for more information, go to website: [http://www.acmg.net/resources/policies/ACT/ACT-sheet_Phenylalanine_5-2-06_ljo.pdf](http://www.acmg.net/resources/policies/ACT/ACT-sheet_Phenylalanine_5-2-06_ljo.pdf)

**Physical phenotype**  
No abnormalities present at birth. May develop widely-spaced incisors, pes planus, epicanthus and microcephaly.

**Inheritance**  
Autosomal recessive

**General population incidence**  
1:10,000

**Ethnic differences**  
Yes

**Population**  
Turks, Irish

**Ethnic incidence**  
Turks (1:2600), Irish (1:4500)

**Enzyme location**  
Liver

**Enzyme Function**  
Converts phenylalanine to tyrosine

**Missing Enzyme**  
Phenylalanine hydroxylase

**Metabolite changes**  
Increased plasma phenylalanine, increased phenylpyruvic acid in urine, decreased plasma tyrosine.

**Prenatal testing**  
DNA testing is possible if mutations known. RFLP analysis is successful in 75% of families.

**MS/MS Profile**  
N/A

**OMIM Link**  

**Genetests Link**  
[www.geneclinics.org](http://www.geneclinics.org)

**Support Group**  
National Urea Cycle Disorders Foundation  
[http://www.nucdf.org](http://www.nucdf.org)  
National Coalition for PKU and Allied Disorders  
Children Living with Inherited Metabolic Diseases  
<table>
<thead>
<tr>
<th><strong>Disease Name</strong></th>
<th>Propionic academia</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Alternate name(s)</strong></td>
<td>Propionyl-CoA carboxylase deficiency, PCC deficiency, Ketotic hyperglycinemia</td>
</tr>
<tr>
<td><strong>Acronym</strong></td>
<td>PA</td>
</tr>
<tr>
<td><strong>Disease Classification</strong></td>
<td>Organic Acid Disorder</td>
</tr>
<tr>
<td><strong>Variants</strong></td>
<td>Yes</td>
</tr>
<tr>
<td><strong>Variant name</strong></td>
<td>Late onset (&gt; 6weeks)</td>
</tr>
<tr>
<td><strong>Symptom onset</strong></td>
<td>Neonatal</td>
</tr>
<tr>
<td><strong>Symptoms</strong></td>
<td>Episodic crises leading to neurologic damage, coma and death.</td>
</tr>
<tr>
<td><strong>Natural history without treatment</strong></td>
<td>Metabolic crises may lead to neurologic damage including mental retardation, movement disorders, seizures. Coma and sudden death are also possible.</td>
</tr>
<tr>
<td><strong>Natural history with treatment</strong></td>
<td>If treatment instituted before metabolic crisis, normal IQ and development may be seen. Treatment may improve some symptoms of affected individuals.</td>
</tr>
<tr>
<td><strong>Treatment</strong></td>
<td>Protein restricted diet with supplementary medical formula, carnitine supplementation, ketone monitoring, avoidance of fasting, cornstarch supplementation, biotin supplementation. Antibiotic (metronidazole and neomycin) treatment. Human growth hormone therapy.</td>
</tr>
<tr>
<td><strong>Emergency Medical Treatment</strong></td>
<td>See sheet from American College of Medical Genetics (attached) or for more information, go to website: <a href="http://www.acmg.net/resources/policies/ACT/ACT-sheet-C3_5-3-06_ljo.pdf">http://www.acmg.net/resources/policies/ACT/ACT-sheet-C3_5-3-06_ljo.pdf</a></td>
</tr>
<tr>
<td><strong>Physical phenotype</strong></td>
<td>Characteristic facies including frontal bossing, widened depressed nasal bridge, epicanthal folds, long philtrum, upturned curvature of the lips and possible hypoplastic/inverted nipples.</td>
</tr>
<tr>
<td><strong>Inheritance</strong></td>
<td>Autosomal recessive</td>
</tr>
<tr>
<td><strong>General population incidence</strong></td>
<td>1:35,000 to 1:75,000 (may be underestimate as infants may die undiagnosed)</td>
</tr>
<tr>
<td><strong>Ethnic differences</strong></td>
<td>Yes</td>
</tr>
<tr>
<td><strong>Population</strong></td>
<td>Saudi Arabia</td>
</tr>
<tr>
<td><strong>Ethnic incidence</strong></td>
<td>1:2000 to 1:5000</td>
</tr>
<tr>
<td><strong>Enzyme location</strong></td>
<td>Mitochondria</td>
</tr>
<tr>
<td><strong>Enzyme Function</strong></td>
<td>Intermediary in the metabolism of isoleucine, valine, threonine and methionine.</td>
</tr>
<tr>
<td><strong>Missing Enzyme</strong></td>
<td>Propionyl-CoA carboxylase</td>
</tr>
<tr>
<td><strong>Metabolite changes</strong></td>
<td>Increased glycine in blood and urine, 3-hydroxypropionic acid in blood and urine, methylcitrate, tiglic acid, tiglyglycine butanone and propionyl glycine in urine.</td>
</tr>
<tr>
<td><strong>Prenatal testing</strong></td>
<td>Enzyme activity in amniocytes. GCMS assay in amniotic fluid. If DNA mutations known, DNA testing is possible.</td>
</tr>
<tr>
<td><strong>MS/MS Profile</strong></td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Genetests Link</strong></td>
<td><a href="http://www.genetests.org">www.genetests.org</a></td>
</tr>
</tbody>
</table>
**Disease Name** | Short-chain acyl-CoA dehydrogenase deficiency  
--- | ---  
**Acronym** | SCADD or SCAD  
**Disease Classification** | Fatty Acid Oxidation Disorder  
**Variants** | Yes  
**Variant name** | Late-onset with chronic myopathy  
**Symptom onset** | Neonatal - but very variable; may be asymptomatic.  
**Symptoms** | Neonatal - failure to thrive, hypotonia, metabolic acidosis, seizures and developmental delay.  
**Natural history** | Developmental delay, hypotonia and muscle weakness have been observed, but the vast *without treatment* majority of patients detected via MS/MS newborn screening have been entirely asymptomatic.  
**Natural history with treatment** | The efficacy of treatment is unknown.  
**Treatment** | Carnitine supplementation, restriction of dietary fat. A few patients have shown improvements on riboflavin supplements.  
**Other** | Acute fatty liver of pregnancy and HELLP syndrome have been reported as maternal complications in pregnancy, but may be coincidental.  
**Emergency Medical treatment** | See sheet from American College of Medical Genetics (attached) or for more information, go to website: http://www.acmg.net/resources/policies/ACT/ACT_sheet_C4_5-3-06_ljo.pdf  
**Physical phenotype** | None reported  
**Inheritance** | Autosomal recessive  
**General population incidence** | 1:40,000 – 1:100,000  
**Ethnic differences** | None  
**Population** | N/A  
**Ethnic incidence** | N/A  
**Enzyme location** | Mitochondrial matrix in liver, muscle, fibroblasts  
**Enzyme Function** | Missing Enzyme  
**Missing Enzyme** | Short-chain acyl-CoA dehydrogenase  
**Metabolite changes** | Ethymalonic acid in urine, methylsuccinate and butyrylglycines in urine.  
**Gene** | ACADS  
**Gene location** | 12g22-qter  
**DNA testing available** | Yes - but interpretation of results is difficult.  
**DNA testing detail** | Limited mutational hotspots and common susceptibility alleles  
**Prenatal testing** | Enzymatic  
**MS/MS Profile** | Elevated C4 Cbutyrylcarnitine  
**Genetests Link** | [www.genetests.org](http://www.genetests.org)  
**Support Group** | FOD Family Support Group  
**Organic Acidemia Association** | [http://www.ooanews.org](http://www.ooanews.org)  
**Save Babies through Screening Foundation** | [http://savebabies.org](http://savebabies.org)
### Disease Name
Sickle Cell Disease

### Alternate Name(s)
Sickle Cell Anemia

### Acronym
Hb S/S

### Disease Classification
Hemoglobinopathy

### Symptom onset
May be asymptomatic.

### Symptoms
Any sign of illness in an infant with sickling disease is a potential medical emergency. Acute and chronic tissue injury can occur when sickled cells cause vascular occlusion. Sickling diseases can cause severe pain anywhere in the body, but most often in the hands, arms, chest, legs and feet. Complications may include, but are not limited to, the following: sepsis, acute chest syndrome, hand-and-foot syndrome, splenic sequestration crisis, aplastic crisis, stroke and painful episodes.

### Natural history without treatment
Infants with sickle cell disease are vulnerable to serious bacterial infections that can be life threatening.

### Natural history with treatment
Reduced mortality and morbidity with penicillin prophylaxis.

### Treatment
The National Institutes of Health clinical guidelines for management of sickle cell disease state, "Penicillin prophylaxis should begin by 2 months of age for infants with suspected sickle cell anemia, whether or not the definitive diagnosis has been established." Antibiotic therapy should continue until at least 5 years of age.

### Emergency Medical Treatment
See sheet from American College of Medical Genetics (attached) or for more information, go to website: [http://www.acmg.net/resources/policies/ACT/ACT-sheet_HBSC_FSC_4-18-06.pdf](http://www.acmg.net/resources/policies/ACT/ACT-sheet_HBSC_FSC_4-18-06.pdf)

### Inheritance
Autosomal recessive

### General population incidence
1:500 for African American and Hispanic American.

### OMIM Link

### Genetests Link
[www.geneclinics.org](http://www.geneclinics.org)

### Support Group
#### Sickle Cell Information Center

#### Sickle Cell Disease Association of America, Inc.
[http://www.sicklecelldisease.org](http://www.sicklecelldisease.org)

9/15/06 Updated
Disease Name: Trifunctional protein deficiency

Alternate name(s): N/A
Acronym: LCHADD/TFP

Disease Classification: Fatty Acid Oxidation Disorder

Variants: Yes

Variant name: Mitochondrial trifunctional protein deficiency
Symptom onset: Neonatal, infancy
Symptoms: Hypoketotic hypoglycemia, hypotonia, cardiomyopathy, hepatic disease, peripheral neuropathy and pigmentary retinopathy, rhabdomyolysis, sudden death

Natural history without treatment: Possible developmental delay due to damage from hypoglycemic episodes, possible death due to cardiomyopathy or hepatic failure.
Natural history with treatment: Intelligence is usually normal if there is no damage due to hypoglycemic crisis. Peripheral neuropathy, if present, may not improve with treatment.

Treatment: Avoidance of fasting, use of uncooked starch, MCT treatments, carnitine supplementation, DHA supplementation (may prevent retinopathy, but this has not been proven)

Other: Maternal complications in pregnancy include acute fatty liver of pregnancy, HELLP syndrome, and pre-eclampsia

Emergency Medical Treatment: See sheet from American College of Medical Genetics (attached) or for more information, go to website: http://www.acmg.net/resources/policies/ACT/ACT_sheet_C16-OH_5_3_06.pdf

Physical phenotype: Hypotonia, cardiomyopathy and possible retinal changes
Inheritance: Autosomal recessive

General population incidence: Rare
Ethnic differences: Yes
Population: Finnish
Ethnic incidence: 1:240 carrier rate for common mutation G1528C in Finland

Enzyme location: Inner mitochondrial membrane, liver, heart, fibroblasts
Enzyme Function: Metabolizes long chain fatty acids (C-12 to C-16 in length)

Missing Enzyme: Long-chain 3-hydroxyacyl-CoA dehydrogenase or mitochondrial trifunctional protein
Metabolite changes: Increased 3-hydroxydicarboxylic acids in urine, increased saturated and unsaturated 3-hydroxy organic acids, possible elevated CPK during acute illness.

Prenatal testing: Enzyme analysis, protein analysis and direct DNA (when applicable).
MS/MS Profile: C18:OH, C16:1OH, C16OH
Genetests Link: www.genetests.org
Save Babies through Screening Foundation http://www.savebabies.org
Genetic Alliance http://www.geneticalliance.org
**Disease Name** | **Tyrosinemia, type 1**  
---|---  
**Alternate name(s)** | Hereditary infantile tyrosinemia, Hepatorenal tyrosinemia, Fumarylacetoacetase deficiency, Fumarylacetoacetate hydrolase  
**Acronym** | FAH deficiency  
**Disease Classification** | Amino Acid Disorder  
**Variants** | Yes  
**Variant name** | Tyrosinemia I chronic-type, Tyrosinemia II, Tyrosinemia III  
**Symptom onset** | Infancy  
**Symptoms** | Hepatocellular degeneration leading to acute hepatic failure or chronic cirrhosis and hepatocellular carcinoma, renal Fanconi syndrome, peripheral neuropathy, seizures and possible cardiomyopathy.  
**Natural history without treatment** | Chronic liver disease leading to cirrhosis and hepatocellular carcinoma. Renal tubular disease (Fanconi syndrome) with phosphaturia, aminoaciduria and often glycosuria. May lead to clinical rickets. Peripheral neuropathy. Self-injurious behavior, seizures and cardiomyopathy have been observed. Coagulation problems.  
**Natural history with treatment** | Hepatitic disease may progress despite dietary treatment. NTBC treatment leads to improvements in kidney, liver and neurologic function, but may not affect incidence of liver cancer.  
**Treatment** | Dietary restriction of phenylalanine and tyrosine. NTBC (2-(2-nitro-4-trifluoro-methylbenzoyl)-1,3-cyclohexanedione) treatment which improves hepatic and renal function. Liver transplantation when indicated to prevent hepatocellular carcinoma. Vitamin D to heal rickets.  
**Other** | Unpleasant odor due to accumulation of methionine. Sometimes described as “cabbage-like” odor.  
**Emergency Medical Treatment** | See sheet from American College of Medical Genetics (attached) or for more information, go to website: http://www.acmg.net/resources/policies/ACT/ACT-sheet_tyrosine_5-2-06_ljo.pdf  
**Physical phenotype** | No abnormalities present at birth. May develop widely-spaced incisors, pes planus, epicanthus and microcephaly.  
**Inheritance** | Autosomal recessive  
**General population incidence** | 1:100,000  
**Ethnic differences** | Yes  
**Population** | French Canadian (Saquency-Lac Saint Jean region) 1:20 carrier rate  
**Ethnic incidence** | 1:1846  
**Enzyme location** | Liver, kidney, lymphocytes, fibroblasts  
**Enzyme Function** | Metabolizes fumarylacetoacetic acid into fumaric acid and acetoacetic acid  
**Missing Enzyme** | Fumarylacetoacetate hydrolase  
**Metabolite changes** | Increased urinary succinylacetone, increased tyrosine and methionine in serum, increased alpha fetoprotein.  
**Prenatal testing** | Enzymatic assay of amniocytes or CVS cells. Direct DNA testing in amniocytes or CVS cells if mutations known. Succinylacetone in amniotic fluid.  
**MS/MS Profile** | N/A  
**Genetests Link** | [www.genetests.org](http://www.genetests.org)  
**Support Group** | National Urea Cycle Disorders Foundation [http://www.nucdf.org](http://www.nucdf.org)  
## Disease Name

**Very long-chain acyl-CoA dehydrogenase deficiency**

<table>
<thead>
<tr>
<th>Alternate name(s)</th>
<th>N/A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acronym</td>
<td>VLCADD</td>
</tr>
</tbody>
</table>

### Disease Classification

Fatty Acid Oxidation Disorder

### Variants

Yes

### Variant name

With and without cardiomyopathy

### Symptom onset

Primarily neonatal but some variability.

### Symptoms

Hypoketotic hypoglycemia, hepatomegaly, myopathy, cardiomyopathy, adult-onset myopathy.

### Natural history without treatment

Sudden infant death due to cardiac abnormalities is common.

### Natural history with treatment

Diagnosis and treatment seem to decrease risk for sudden death.

### Treatment

Avoidance of fasting, high carbohydrate, low-fat diet supplemented with MCT oil, IV glucose during illness, cornstarch supplementation, avoidance of long chain fatty acids, possible carnitine supplementation.

### Other

May have history of a sibling dying of SIDS.

### Emergency Medical Treatment

See sheet from American College of Medical Genetics (attached) or for more information, go to website: [http://www.acmg.net/resources/policies/ACT/ACT_sheet_C14-C14_1_5-2-06_ljo.pdf](http://www.acmg.net/resources/policies/ACT/ACT_sheet_C14-C14_1_5-2-06_ljo.pdf)

### Physical phenotype

No particular dysmorphisms. Cardiomyopathy in infants.

### Inheritance

Autosomal recessive

### General population incidence

Rare – exact incidence not known

### Ethnic differences

None reported

### Population

N/A

### Ethnic incidence

N/A

### Enzyme location

Mitochondrial matrix, heart, liver

### Enzyme Function

Long chain fatty acid beta-oxidation

### Missing Enzyme

Very long-chain acyl-CoA dehydrogenase

### Metabolite changes

Diacarboxylic aciduria, decreased urinary carnitine at times of illness, plasma free carnitine - normal to low, increased plasma long-chain acylcarnitines mildly increased ammonia, lactate and creatine kinase.

### Prenatal testing

Enzyme and protein analysis. If a mutation in a proband is detected, DNA prenatal diagnosis via CVS or amniocytes is possible.

### MS/MS Profile

Elevated C16:1, C14:2, C14:1, C18:1

### OMIM Link


### Genetests Link

[www.genetests.org](http://www.genetests.org)

### Support Group

FOD Family Support Group

[http://www.fodsupport.org](http://www.fodsupport.org)

Save Babies through Screening Foundation

[http://www.savebabies.org](http://www.savebabies.org)

Genetic Alliance

[http://www.geneticalliance.org](http://www.geneticalliance.org)
The links to the following Fact Sheets can be found at this link on the internet:

http://chfs.ky.gov/dph/ach/ecd/newbornscreening.htm
PARENT FACT SHEET

DISORDER

3-methylcrotonyl CoA carboxylase deficiency (3MCC)

CAUSE
In order for the body to use protein from the food we eat, it is broken down into smaller parts called amino acids. Special enzymes then make changes to the amino acids so the body can use them. 3MCC deficiency occurs when an enzyme is missing or not working properly.

IF NOT TREATED

Each child with 3MCC deficiency may have somewhat different effects. Babies with 3MCC deficiency are healthy at birth. If symptoms occur, they often start after 3 months of age. Some babies do not have symptoms until 6 months to 3 years of age. If not treated these babies could go into metabolic crisis which could lead to seizures, breathing problems, liver failure, coma or death.

TREATMENT OPTIONS

Your child will need to be under the care of a metabolic specialist and dietician. Treatment is needed throughout the child’s life.

• A food plan low in leucine with limited amounts of protein is sometimes needed. Most food in the diet will be carbohydrates (bread, cereal, pasta, fruit, vegetables).
• Medical foods and formula: special low-protein flours, pastas and rice that are made especially for people with organic acid disorders.
• Some children may benefit by taking a medication called L-carnitine.

IF TREATED

With prompt and careful treatment, children who have shown symptoms of 3MCC deficiency have a good chance to live healthy lives with typical growth and development. Even with treatment, some children still have repeated bouts of metabolic crisis that require close monitoring throughout their life.

For more information go to the following website: http://chfs.ky.gov/dph/ach/ecd/newbornscreening.htm
PARENT FACT SHEET

DISORDER

Argininosuccinic Acidemia (ASA)

CAUSE

ASA occurs when an enzyme called argininosuccinic acid lyase is either missing or not working properly. This enzyme's job is to help remove ammonia from the body. When the ASA lyase enzyme is not working, ammonia and other harmful substances build up in the blood.

IF NOT TREATED

Normally, the body changes ammonia into a substance called “urea.” Urea is then safely removed from the body in the form of urine. If urea is not removed from the body, it begins to build up in the blood and causes brain damage. In the most common form of ASA, infants are generally healthy at birth but usually develop symptoms within a few days of life. Without treatment, many babies die within the first few weeks of life. There is also a second form of ASA in which very mild symptoms start in late infancy or early childhood.

TREATMENT OPTIONS

Your child will need to be under the care of a metabolic specialist and dietician. Treatment is needed throughout the child’s life.

- Most children need to eat a diet made up of very low-protein foods, special medical foods, and sometimes a special formula. The dietician will develop a plan for you to follow.
- Most children with ASA are given arginine supplements. Arginine helps the body remove ammonia from the blood. Your child’s metabolic specialist will determine the best treatment available. Arginine is available by prescription only.
- Your child will require frequent blood tests to monitor amino acid and ammonia levels in the blood. Diet and medication may require adjustments based on these lab results.
- Contact your child’s doctor immediately at the start of any illness. Children with ASA may need to be treated in a hospital to prevent serious health problems.

IF TREATED

With prompt and lifelong treatment, children with ASA may be able to live healthy lives with typical growth and learning. Early treatment can lessen the risk for brain damage and mental retardation by preventing high ammonia levels. Even with treatment, some children still have episodes of high ammonia. This can result in brain damage and can cause lifelong learning problems, mental retardation, and spasticity (spasms of the muscles and tendons).

12/1/05 Update

For more information go to the following website: http://chfs.ky.gov/dph/ach/ecd/newbornscreening.htm
PARENT FACT SHEET

DISORDER

Beta ketothiolase deficiency (BKT)

CAUSE

BKT occurs when the mitochondrial acetoacetyl-CoA thiolase enzyme (MAT) is either missing or not working properly. This enzyme’s job is to help break down the amino acid called isoleucine. Isoleucine is found in all foods that contain protein. When a child with BKT eats food containing isoleucine, harmful substances called organic acids build up in the blood and urine, causing metabolic crisis and brain damage.

IF NOT TREATED

Each child with BKT has slightly different effects. The first symptoms often start around age one, although babies can have symptoms earlier or later than this. BKT causes episodes of illness called metabolic crises, which can cause brain damage, learning disabilities, mental retardation, and other problems.

TREATMENT OPTIONS

Your child will need to be under the care of a metabolic specialist and dietician. Treatment should begin immediately and will continue throughout life.

• Your child needs to avoid going a long time without food. This is to avoid a metabolic crisis. Children with BKT should not go more than 4 to 6 hours without food and some may require more frequent feedings. Your child’s metabolic specialist will advise you as to whether your child needs to eat more often than usual and how to space your child’s meals.
• The dietician will help develop a food plan that meets your child’s needs. Any changes in diet should only be made by the dietician. While some children with BKT can eat normal amounts of protein, others will need to be on a low-protein diet.
• Periodic urine tests should be done to test the level of ketones. This can be done at home or at the doctor’s office. Ketones are substances formed when body fat is broken down to use for energy. This happens after going without food for long periods of time, during illness, or during periods of heavy exercise. Ketones in the urine may signal the start of a metabolic crisis.
• Contact your child’s doctor immediately at the start of any illness. Children with BKT may require hospitalization to prevent metabolic crisis.

IF TREATED

If treatment is started early and metabolic crises do not occur, your child is likely to have normal growth and intelligence. Even with treatment, some children still have repeated episodes of metabolic crises, which can cause brain damage resulting in learning difficulties, mental retardation and other problems.

12/1/05 Update

For more information go to the following website: http://chfs.ky.gov/dph/ach/ecd/newbornscreening.htm
DISORDER

Biotinidase Deficiency (BTD)

CAUSE

BTD affects the way a person’s body uses the vitamin, biotin. Biotin is an important vitamin that helps enzymes, called carboxylases, make certain fats and carbohydrates and help break down proteins. A child with BTD cannot use biotin when it is still bound to food. Biotin can only be used in its free form and is essential for proper growth and development.

IF NOT TREATED

Most infants with BTD appear normal at birth, but develop serious symptoms after the first few weeks or months of life. Low biotin levels can cause seizures, developmental delay, hearing loss, vision problems, and other serious and sometimes life-threatening illnesses.

TREATMENT OPTIONS

Your child will need to be under the care of a metabolic specialist. Treatment is needed throughout life.

- Biotin supplements can be taken orally and come in many forms – capsules, tablets, and liquids. Biotin supplements are safe and non-toxic.
- Your child’s metabolic specialist will determine the proper dose that should be taken.
- A prescription is required for biotin supplements.
- Regular blood work will be required to monitor your child’s progress in the event any changes in treatment need to be made.

IF TREATED

Because newborn screening can detect virtually all cases of BTD, treatment can be started very quickly. If your child begins treatment before showing any symptoms, biotin supplements can prevent all symptoms from occurring. If your child is already showing symptoms, most of those symptoms will improve upon being treated. Biotin therapy will not reverse brain damage that occurs before treatment is started, but it will prevent further damage from occurring. However, vision and hearing loss may not respond to biotin treatment, depending on the time between the beginning of symptoms and the start of treatment. Some children achieve rapid developmental milestones while others show continued developmental delays.

For more information go to the following website: http://chfs.ky.gov/dph/ach/ecd/newbornscreening.htm

12/1/05 Update
PARENT FACT SHEET

DISORDER

Carnitine uptake defect (CUD)

CAUSE

CUD occurs when an enzyme, called “carnitine transporter” (CT), is either missing or not working properly. This enzyme’s job is to carry a substance called carnitine into our cells. Carnitine helps the body make energy from the fat in food and also helps us use fat already stored in the body. When the normal CT enzyme is not functioning properly, the body must rely solely on glucose. There is a limited supply of glucose in our bodies and once it is used up, the body tries to use fat without success. This leads to low blood sugar, called hypoglycemia, and the build up of harmful substances in the blood. This is referred to as a metabolic crisis.

IF NOT TREATED

There are two main forms of CUD: one begins in infancy and the other in childhood. Babies with CUD usually begin showing symptoms between birth and three years old. Metabolic crisis often occurs when a child has not eaten for more than a few hours, gets sick, or develops an infection. Repeated episodes of metabolic crisis can cause brain damage and result in learning problems or mental retardation.

TREATMENT OPTIONS

Your child will need to be under the care of a metabolic specialist and dietician. Treatment is usually needed throughout life.

- Your child needs to avoid going a long time without food. This is to avoid a metabolic crisis. These children should not go more than 4 to 6 hours without food and some may require more frequent feedings. It is important that these children be fed in the night – meaning you will need to wake them up to eat if they do not wake up on their own – and even if they are not hungry.
- The dietician will develop a diet for your child that contains low amounts of fat and a high amount of carbohydrates. Your child’s diet should never be changed without the approval of your dietician.
- The main treatment for CUD is a supplement of L-carnitine. This is a safe and natural substance that helps body cells make energy. It also helps the body get rid of harmful wastes. L-carnitine can reverse the heart problems and muscle weakness that occur in children with CUD.
- Your metabolic specialist must prescribe the L-carnitine supplement and instruct you on the recommended dose.
- Contact your child’s doctor immediately at the start of any illness. Children with CUD need to be treated in a hospital to prevent serious health problems.

IF TREATED

With prompt and careful treatment, children with CUD usually live healthy lives with typical growth and development. Infants with CUD who have repeated episodes of metabolic crisis may have permanent brain damage. This can cause learning disabilities or mental retardation.

12/1/05 Update

For more information go to the following website: http://chfs.ky.gov/dph/ach/ecd/newbornscreening.htm
DISORDER

Citrullinemia (CIT)

CAUSE

CIT occurs when an enzyme called “argininosuccinic acid synthetase” (ASAS), is either missing or not working properly. This enzyme's job is to help break down certain amino acids and to remove ammonia from the body. When the enzyme is not working, an amino acid called citrulline builds up in the blood. Ammonia and other harmful substances also build up. This causes brain damage and, if not treated, can cause death.

IF NOT TREATED

Normally, the body changes ammonia into a substance called “urea.” Urea is then safely removed from the body in the form of urine. If urea is not removed from the body, it begins to build up in the blood and causes brain damage. In the most common form of CIT, infants may seem healthy at birth but develop symptoms within the first few days of life. There is also a milder form of CIT in which symptoms start in late infancy or early childhood. Without treatment, most babies die within the first few weeks of life.

TREATMENT OPTIONS

Your child will need to be under the care of a metabolic specialist and dietician. Treatment is usually needed throughout life.

- Most children need to eat a diet made up of very low-protein foods, special medical foods, and sometimes a special formula. The dietician will develop a plan for you to follow.
- Most children with CIT are given arginine supplements. Arginine helps the body remove ammonia from the blood. Your child’s metabolic specialist will determine the best treatment available. Arginine is available by prescription only.
- Your child will require frequent blood tests to monitor amino acid and ammonia levels in the blood. Diet and medication may require adjustments based on these lab results.
- Contact your child’s doctor immediately at the start of any illness. Children with CIT may need to be treated in a hospital to prevent serious health problems.

IF TREATED

With prompt and lifelong treatment, children with CIT may be able to live healthy lives with typical growth and learning. Early treatment can lessen the risk for brain damage and mental retardation by preventing high ammonia levels. Even with treatment, some children still have episodes of high ammonia. This can result in brain damage and can cause lifelong learning problems, mental retardation, and spasticity (spasms of the muscles and tendons).

For more information go to the following website: http://chfs.ky.gov/dph/ach/ecd/newbornscreening.htm

12/1/05 Update -8L-
PARENT FACT SHEET

DISORDER

Congenital Adrenal Hyperplasia (CAH)

CAUSE

In CAH, the child is born with overgrown adrenal glands, which are unable to make enough cortisol. Cortisol is essential for life, as it is needed to maintain an adequate energy supply and blood sugar level. Cortisol is also called a “stress hormone” because our adrenal glands make more of it when we are under physical or emotional stress to protect our bodies from illness or injury. Another important hormone made by the adrenal gland is called aldosterone, a salt-retaining hormone. Aldosterone is used by the kidney to help the body maintain normal levels of sodium and potassium, which are necessary for all cells to work normally. Without adequate levels of these minerals in the body, too much salt and water are lost in the urine, leading to salt deficiency and dehydration. Children with CAH also produce too much androgen (male hormone). The overproduction of male hormone in female infants will cause the external genitals to take on a male appearance, although the internal parts may be quite normal. For this reason, females are more likely to be diagnosed earlier than boys. Boys are likely to be diagnosed as a result of entering puberty at an extremely early age (some as young as 2-3 years old) and appearing to be very tall for their age.

IF NOT TREATED

Untreated CAH can result in serious illness due to salt-wasting and, in some cases, death. It may be difficult to tell if the CAH child’s genitals are male or female. Without treatment, the clitoris in the female infant will continue to enlarge into a male-like penile structure. Untreated females do not have normal periods and are unable to have children as an adult. The testicles of a boy with CAH cannot function well and will not make sperm normally. High levels of androgens cause rapid early physical growth that will also stop prematurely, resulting in the child becoming a very short adult.

TREATMENT OPTIONS

Your child will need to be under the care of a metabolic specialist. CAH cannot be “outgrown” and treatment will be needed throughout life.

- CAH is treated with hormone-replacement medications. The metabolic specialist will determine the proper amount your child should take each day. These medications will require a prescription.
- Reconstructive surgery may be required for girls with masculine external genitalia and can be performed as early as one to three months of age.
- Blood tests will need to be performed frequently to monitor hormone levels and adjust medications as necessary.
- Contact your child’s doctor immediately at the start of any illness. Children with CAH may need to be treated at a hospital to prevent serious health problems.

IF TREATED

With regular medication, your child with CAH can lead a normal life. There are no known mental delays associated with CAH. Life expectancy is normal. Women with CAH that take their medications as directed have no difficulties becoming pregnant and carrying a baby to term. Men who take their medications appropriately also have normal fertility.

12/1/05 Update -8N-

For more information go to the following website: http://chfs.ky.gov/dph/ach/ecd/newbornscreening.htm
DISORDER

Congenital Hypothyroidism (CH)

CAUSE

The thyroid gland is responsible for producing the hormone, thyroxine (T4). Thyroxine is very important in the growth and development of the infant’s brain, body, bone development, in regulating the infant’s body temperature, and in making sure that fat and muscle are distributed normally throughout the body. Under normal circumstances, the thyroid gland is regulated by the pituitary gland. The pituitary gland recognizes when the body is not producing enough T4 and produces thyroid stimulating hormone (TSH). There are a variety of causes for CH. The thyroid gland may never have developed. The thyroid gland may have developed abnormally or be smaller than normal. The thyroid could even be misplaced to an abnormal location.

IF NOT TREATED

There is a high rate of severe mental retardation and growth delays in untreated children with CH or in those children who were delayed in beginning treatment.

TREATMENT OPTIONS

Your child will need to be under the care of a metabolic specialist. Treatment is needed throughout life.

- Your child will require thyroid replacement medications. The metabolic specialist will prescribe these medications and make adjustments in the dosage as necessary.
- Remember to never mix thyroid medications with soy formula as the baby will be unable to absorb the medication and will not receive the medication’s benefits.

IF TREATED

Children that are treated within the first month to six weeks of life can prevent mental retardation, even to the point of having no mental or physical delays, allowing them to lead normal lives. Treatment that begins after 4-6 weeks of life may not reverse any mental impairments that have already occurred, but it can reverse physical impairments that have already occurred.

For more information go to the following website: http://chfs.ky.gov/dph/ach/ecd/newbornscreening.htm
Cystic Fibrosis (CF)

CAUSE

CF is an inherited disease that causes the exocrine glands to not work properly. The exocrine glands normally make thin, slippery secretions like sweat, mucus, tears, saliva, and digestive juices. In CF, the exocrine glands make thick, sticky mucus that may plug passageways (ducts) to the lungs, intestines, and other organs. Children with CF also have a high amount of salt and potassium in their sweat, which may cause problems during times of increased sweating. CF is not contagious and does not affect the brain. Most infants with CF are diagnosed within the first three years of life. As adults, the reproductive system will also be affected by CF. The thick mucus blocks the passageway for men to pass sperm and, in women with CF, blocks sperm from reaching the egg. Approximately 98 percent of men with CF are unable to father a child. Women with CF may have greater difficulty getting pregnant than women without CF.

IF NOT TREATED

The thick mucus caused by CF can clog the child’s airway and make it difficult to breathe. It can also cause frequent lung infections. Because of the high amount of minerals lost during sweating, it is very easy for a child with CF to become dehydrated when they become overheated. The thick mucus caused by CF also keeps food from being properly digested, resulting in poor growth and malnutrition or a blockage in the intestine that requires medical treatment. Any of these events, in an untreated child with CF, are potentially life-threatening.

TREATMENT OPTIONS

Your child will need to be under the care of a cystic fibrosis specialist and a dietician. Treatment is required throughout life.

• The child with CF will need to take pancreatic enzymes to help with digestion. They may also have to take numerous other medications every day. These will be prescribed by their cystic fibrosis specialist.
• Daily lung percussion (clapping the hand on the child’s chest and back) is often required for the CF child. This can be done in your home and usually lasts for 30 minutes each session, twice a day. The CF specialist will train you on the proper way to do this.
• Your child will also require daily respiratory medications that may be given in a pill, as a vapor (by being inhaled), or through the vein. This helps thin the mucus in the lungs and prevents lung infections from occurring.
• There should be absolutely no cigarette smoking around a child with CF!!!!
• Contact your child’s doctor immediately at the start of any illness. Children with CF may need to be treated in a hospital when ill to prevent serious health problems.

IF TREATED

With treatment, children with CF are seeing an increased life expectancy and are living active lives.

For more information go to the following website: [http://chfs.ky.gov/dph/ach/ecd/newbornscreening.htm](http://chfs.ky.gov/dph/ach/ecd/newbornscreening.htm)
PARENT FACT SHEET

DISORDER

Galactosemia (GALT)

CAUSE

GALT is caused when the liver enzyme that helps the body break down galactose (a form of milk sugar) is either missing or not working properly. Since galactose cannot be broken down in a child with GALT, it builds up in the body and causes damage to the liver, brain, kidneys, eyes, and various other body systems.

IF NOT TREATED

Babies with GALT may appear normal at birth, but their condition can rapidly worsen if they are given any form of human or animal milk products. Exposure to milk products may result in liver damage, mental retardation, cataract formation, partial blindness, and kidney failure – to the point where death can occur as early as one to two weeks of age.

TREATMENT OPTIONS

Your child will need to be under the care of a metabolic specialist and dietician. Treatment will be needed throughout life.

- Your child’s metabolic specialist and dietician will put your child on a soy-based formula and develop a diet plan, as your child gets older.
- As the patient with GALT must avoid any food that contains milk or milk products, you will have to learn to read product ingredient labels at the grocery in order to also avoid foods that may contain dry milk products, as well.

IF TREATED

If diagnosis is made early and milk products are strictly avoided, the child with GALT can expect to live a relatively normal life. However, mild mental delays may still develop in GALT patients despite strict avoidance of galactose.

For more information go to the following website: http://chfs.ky.gov/dph/ach/ecd/newbornscreening.htm

12/1/05 Update
PARENT FACT SHEET

DISORDER

Glutaric acidemia type 1 (GA-1)

CAUSE

GA-1 occurs when an enzyme called “glutaryl-CoA dehydrogenase” is either missing or not working properly. This enzyme’s job is to break down a substance called glutaric acid. Glutaric acid is made when the amino acids lysine, hydroxylysine, and tryptophan are processed by the body. Whenever a child with GA-1 eats a food containing lysine or tryptophan, glutaric acid and other harmful substances build up in the blood. Lysine and tryptophan are found in all foods that contain protein.

IF NOT TREATED

Babies with GA-1 are usually healthy at birth, although many are born with a larger-than-average head size. Other symptoms usually start between two months and four years of age. GA-1 causes episodes of severe illness called metabolic crises. A metabolic crisis can cause brain damage and problems with involuntary movements of the muscles and tendons (this is called spasticity).

TREATMENT OPTIONS

Your child will need to be under the care of a metabolic specialist and dietician. Treatment is needed throughout life.

- Your child’s dietician will develop a food plan made up of foods low in lysine and tryptophan. A special formula will need to be given to your child as an infant. Special medical foods will also be part of this food plan.
- No changes to your child’s diet should occur without permission and supervision of the dietician.
- Riboflavin is a vitamin that helps the body use protein. It may also help remove glutaric acid from the blood. Your child’s metabolic specialist will prescribe the proper dose and make any changes when necessary.
- Some children may be helped by taking L-carnitine. This is a safe and natural substance that helps the body make energy. It also helps the body get rid of harmful wastes. Your metabolic specialist will prescribe this medication, if necessary.
- Your child will have regular blood tests to measure their amino acid levels. Urine tests may also need to be done. The results of these tests may result in medication or diet changes.
- Children with GA-1 need to eat more carbohydrates and drink more fluids when they are ill – even when they are not hungry. They also should avoid all protein when they are ill.
- Contact your child’s doctor immediately at the start of any illness. Children with GA-1 may need to be treated in a hospital to prevent serious health problems.

IF TREATED

With prompt and lifelong treatment, children with GA-1 can often live healthy lives with typical growth and learning.

12/1/05 Update

For more information go to the following website: http://chfs.ky.gov/dph/ach/ecd/newbornscreening.htm
Parent Fact Sheet

**DISORDER**

**Hemoglobin S-βeta Thalassemia disease (Hb S/β)**

**CAUSE**

B (Beta) thalassemia is a type of inherited blood disorder that can cause anemia (a low number of red blood cells). It affects a person’s ability to produce hemoglobin, the protein in red blood cells that delivers oxygen to all parts of the body.

Signs and symptoms of β (beta) thalassemia are severe in the form of the disorder known as thalassemia major and less severe in the form called thalassemia intermedia. Signs and symptoms of thalassemia major appear in the first 2 years of life. Infants become pale and listless, have a poor appetite, grow slowly, and often develop jaundice (yellowing of the skin). The spleen, liver, and heart may also be enlarged.

**IF NOT TREATED**

Most children with thalassemia major appear healthy at birth, but during the first year or two of life they become pale, listless and fussy, and have a poor appetite. They grow slowly and often develop jaundice (yellowing of the skin). Adolescents with the severe form may experience delayed puberty. Individuals with thalassemia intermedia may have no symptoms or mild symptoms through childhood and adolescence.

Without treatment, the spleen, liver, and heart soon become greatly enlarged. Bones become thin and brittle; face bones become distorted, and children with thalassemia often look alike. Heart failure and infection are the leading causes of death among children with untreated thalassemia major.

**TREATMENT OPTIONS**

- The use of frequent blood transfusions and antibiotics has improved the outlook for children with thalassemia major. When children with thalassemia major are treated with frequent transfusions (generally every 3 to 4 weeks) aimed at keeping their hemoglobin level near normal, many of the complications of thalassemia can be prevented. This form of treatment, referred to as "hypertransfusion," enhances the child’s growth and well-being, and usually prevents heart failure and bone deformities.
- Contact your child’s doctor immediately at the start of any illness

**IF TREATED**

Children with thalassemia major who are treated with frequent blood transfusions and iron chelation live longer. Since intensive chelation treatment was introduced only in the 1960s, continuing studies may show that treated individuals are living even longer.

Thalassemia has been cured using bone marrow transplants. However, this form of treatment is possible only for a small minority of patients who have a suitable bone marrow donor, and the transplant procedure is still risky and can result in death.

12/1/05 Update -8X-

For more information go to the following website: [http://chfs.ky.gov/dph/ach/ecd/newbornscreening.htm](http://chfs.ky.gov/dph/ach/ecd/newbornscreening.htm)
Hemoglobin S/C Disease (Hb S/C)

CAUSE
Sickle cell disease is an inherited blood disorder characterized by defective hemoglobin (a protein in red blood cells that carries oxygen to the tissues of the body).

Sickle cells only live for about 15 days, while normal hemoglobin can live up to 120 days. Also, sickle cells risk being destroyed by the spleen because of their shape and stiffness. The spleen is an organ that helps filter the blood of infections and sickled cells get stuck in this filter and die. Due to the decreased number of hemoglobin cells circulating in the body, a person with sickle cell disease is chronically anemic. The spleen also suffers damage from the sickled cells blocking healthy oxygen carrying cells. Without a normal functioning spleen, these individuals are more at risk for infections. Infants and young children are at risk for life-threatening infections.

Sickle cell - hemoglobin C disease - The child has both HbS and HbC. This is often referred to as HbSC. Hemoglobin C causes red blood cells, called target cells, to develop. Having just some hemoglobin C and normal hemoglobin, a person will not have any symptoms of anemia. However, if the sickle hemoglobin S is combined with the target cell, some mild to moderate anemia may occur. These children often suffer some of the complications associated with HbSS, sickle cell disease, but to a milder degree. Vasoocclusive crises (the flow of blood is blocked because the sickled cells have become stuck in the blood vessels), organ damage from repeated sickling and anemia, and high risk for infection are all similar traits for HbSS and HbSC.

TREATMENT OPTIONS
- Pain medications (for sickle cell crises).
- Drinking plenty of water daily (8 to 10 glasses) or receiving fluid intravenously (to prevent and treat pain crises).
- Blood transfusions (for anemia, and to prevent stroke; transfusions are also used to dilute the HbS with normal hemoglobin to treat chronic pain, acute chest syndrome, splenic sequestration and other emergencies.)
- Penicillin (to prevent infections).
- Folic acid (to help prevent severe anemia).
- Hydroxyurea (a medication recently developed that may help reduce the frequency of pain crises and acute chest syndrome; it may also help decrease the need for frequent blood transfusions. The long-term effects of the medication are unknown.)
- Bone marrow transplant (has been effective in curing some children with sickle cell disease; the decision to undergo this procedure is based on the severity of the disease and a suitable bone marrow donor. These decisions need to be discussed with your child’s physician.)

IF TREATED
With early detection and comprehensive medical care, most people with sickle cell disease are in fairly good health most of the time. Most individuals can be expected to live well into adulthood, enjoying an improved quality of life including the ability to choose a variety of education, career, and family planning options for themselves.

For more information go to the following website: http://chfs.ky.gov/dph/ach/ecd/newbornscreening.htm
**PARENT FACT SHEET**

**DISORDER**

Homocystinuria (HCY)

**CAUSE**

HCY occurs when an enzyme called “cystathionine beta-synthase” (CBS) is either missing or not working properly. This enzyme’s job is to break down methionine, an amino acid. When the CBS enzyme is not working correctly, methionine and another amino acid, homocystine, build up in the blood and cause problems.

**IF NOT TREATED**

Babies with HCY look healthy and normal at birth. If the condition is not treated, HCY can cause growth and learning delays, which are usually noticed between one and three years of age. HCY can also affect the eyes, bones, heart, and blood vessels.

**TREATMENT OPTIONS**

Your child will need to be under the care of a metabolic specialist and dietician. Treatment is needed throughout life.

- The infant with HCY will require a special formula, which will be prescribed by the metabolic specialist and dietician.
- As your child gets older, the dietician will develop a special food plan, which may include special medical foods.
- The metabolic specialist will prescribe medications for your child and the proper amounts to give. These will include Vitamin B6, Betaine, Vitamin B12, Folic Acid, and L-cystine.
- Do not make any changes to medications or diet without the approval and permission of the metabolic specialist and the dietician.
- Your child will require regular blood and urine tests to check their amino acid levels. Diet and medication changes may occur as a result.
- Contact your child’s doctor immediately at the start of any illness. Children with HCY may need to be treated in a hospital to prevent serious health problems.

**IF TREATED**

With lifelong treatment, many children experience normal growth and learning abilities. Treatment may lower the risk of blood clots, heart disease and stroke. Treatment also decreases the chance of eye problems. Children who begin treatment later in life may have mental retardation and behavior problems.

12/1/05 Update -8AB-

For more information go to the following website: [http://chfs.ky.gov/dph/ach/ecd/newbornscreening.htm](http://chfs.ky.gov/dph/ach/ecd/newbornscreening.htm)
PARENT FACT SHEET

DISORDER

Hydroxymethylglutaric Aciduria (3-OH 3 CH₃ glutaric aciduria) (HMG)

CAUSE

HMG occurs when the HMG CoA lyase enzyme is missing or not working properly. This enzyme breaks down leucine, which is found in all foods that contain protein, and helps the body make ketones, used from fat stored in the body to produce energy. When a child is ill or goes without food too long, the body breaks down its own protein and fat to use for energy. Because of the deficient HMG CoA lyase enzyme, this can cause a metabolic crisis due to the HMG child’s inability to process leucine and produce ketones.

IF NOT TREATED

HMG can exhibit different effects in each child. Babies with this condition are usually healthy at birth, although some show their first symptoms a few days after birth. Most babies, however, start to have symptoms between 3 months and 2 years of age. If not treated, many babies die during their first metabolic crisis. In surviving babies, repeated episodes of metabolic crisis can cause brain damage. This can result in life-long learning problems or mental retardation.

TREATMENT OPTIONS

Your child will need to be under the care of a metabolic specialist and dietician. Treatment is usually needed throughout life.

- Your child needs to avoid going a long time without food. This is to avoid a metabolic crisis. These children should not go more than 4 to 6 hours without food and some may require more frequent feedings. It is important that these children be fed in the night – meaning you will need to wake them up to eat if they do not wake up on their own – and even if they are not hungry.
- A low-leucine diet with limited amounts of fat and protein and a high amount of carbohydrates is often recommended by the dietician in the form of special formula and foods.
- Some children may benefit from taking L-carnitine. This is a safe and natural substance that helps the body make energy. The metabolic specialist will decide if your child can benefit from this treatment. A prescription for this is required.
- Contact your child’s doctor immediately at the start of any illness. Children with HMG need to be treated in a hospital to prevent serious health problems.

IF TREATED

With prompt and careful treatment, children with HMG lyase deficiency have a good chance to live healthy lives with typical growth and development. Even with treatment, some children still have repeated episodes of low-blood sugar and metabolic crisis. This can cause brain damage and may lead to life-long learning problems or mental retardation.

12/1/05 Update

For more information go to the following website: http://chfs.ky.gov/dph/ach/ecd/newbornscreening.htm
PARENT FACT SHEET

DISORDER

Isovaleric Acidemia (IVA)

CAUSE

IVA occurs when an enzyme called “isovaleryl-CoA dehydrogenase” is either missing or not working properly. This enzyme’s job is to help break down a harmful substance called isovaleric acid. It is made in the body when the amino acid, leucine, is broken down. When a child with IVA eats food containing leucine, isovaleric acid builds up in the blood and causes problems. Leucine is found in all foods that contain protein.

IF NOT TREATED

Infants with IVA seem healthy at birth. Often, the first symptoms start between one day and two weeks of age. IVA causes episodes of illness called metabolic crises. If not treated, many babies die during their first metabolic crisis. In those who survive, repeated episodes of metabolic crisis can cause brain damage. This can result in life-long learning problems or mental retardation.

TREATMENT OPTIONS

Your child will need to be under the care of a metabolic specialist and dietician. Treatment is usually needed throughout life.

- The infant with IVA will require a special formula, which will be prescribed by the metabolic specialist and the dietician.
- As your child gets older, the dietician will develop a special food plan, which may include special medical foods.
- Glycine is an amino acid that helps the body get rid of isovaleric acid. It is often given as a supplement to children with IVA. It may help prevent metabolic crises. Your child’s metabolic specialist will prescribe this supplement and the correct amount to take, if necessary.
- Some children may benefit by taking L-carnitine. This is a safe and natural substance that helps the body make energy. It also helps the body get rid of isovaleric acid and other harmful wastes. The metabolic specialist will decide whether or not your child needs L-carnitine and, if so, the proper amount they should take.
- Do not make any changes to medications or diet without the approval and permission of the metabolic specialist and the dietician.
- Contact your child’s doctor immediately at the start of any illness. Children with IVA may need to be treated in a hospital to prevent serious health problems.

IF TREATED

With prompt and careful treatment, children with IVA have a good chance to live healthy lives with typical growth and development. However, even when treated, some children still have repeated occurrences of metabolic crisis, which can lead to life-long learning problems or mental retardation.

12/1/05 Update

For more information go to the following website: http://chfs.ky.gov/dph/ach/ecd/newbornscreening.htm
PARENT FACT SHEET

DISORDER

Long Chain 3-hydroxyacyl-CoA dehydrogenase deficiency (LCHAD)

CAUSE

People with LCHAD have problems breaking down fatty acids into energy for the body. LCHAD occurs when an enzyme called long chain 3-hydroxyacyl-CoA dehydrogenase is either missing or not working properly. When this enzyme is missing or not working properly the body cannot break down fat for energy so it relies on glucose, which the body only has limited amounts. Once the glucose is used up, the body tries to use fats without success. This leads to low blood sugar and the buildup of harmful substances in the blood.

IF NOT TREATED

The symptoms can vary from person to person. Hypoglycemia (low blood sugar) is usually the first symptom of a metabolic crisis. If the metabolic crisis is not treated, then the baby can have breathing problems, swelling of the brain, seizures and coma, sometimes leading to death.

If not treated the baby may have poor weight gain, delays in learning, delays in walking and other motor skills, enlarged liver, enlarged heart, vision loss, anemia, nerve problems and bouts of muscle weakness and pain.

TREATMENT OPTIONS

• Your doctor will work with a metabolic specialist and dietician to care for your child.
• Avoid hypoglycemia by having your baby eat at least every 4-6 hours; some babies may need to eat more often. It is important to feed them even during the night. They need to be woken up to eat if they do not wake up on their own.
• A diet high in carbohydrates and low in fat is recommended. Any diet changes should be made under the guidance of a dietician.
• MCT oil and L-Carnitine are often used as part of the food plan for people with LCHAD. Your metabolic doctor will guide you on how to use and will give you a prescription for these.
• Call your doctor at the start of any illness.
• Avoid prolonged exercise or exertion.

IF TREATED

Children who are treated early usually live healthy lives with typical growth and development. Some children continue to have episodes of hypoglycemia even with treatment. Some people still have vision, muscle, liver or heart problems even with treatment.

12/1/05 Update
For more information go to the following website: http://chfs.ky.gov/dph/ach/ecd/newbornscreening.htm
Parent Fact Sheet
Maple Syrup Urine Disease (MSUD)

CAUSE

MSUD stands for "maple syrup urine disease". It is named for the sweet maple syrup smell of the urine in untreated babies. This condition is one type of amino acid disorder. People with MSUD have problems breaking down certain amino acids found in protein.

Classic MSUD, the most common form, is caused by the absence of a group of enzymes called "branched-chain ketoacid dehydrogenase" (BCKAD). The job of this enzyme group is to break down three different amino acids called leucine, isoleucine and valine. When they cannot be broken down, these amino acids build up in the blood and cause problems.

Symptoms start as soon as a baby is fed protein, usually shortly after birth. Babies with MSUD have episodes of illness called metabolic crises. A metabolic crisis can cause severe health problems and, sometimes, even death.

IF NOT TREATED

The untreated child with MSUD can have repeated episodes of metabolic crisis. Symptoms of a metabolic crisis often occur after going too long without food, during illness or infection and during stressful events such as surgery.

Without treatment, brain damage can occur. This can cause mental retardation or spasticity. Some babies become blind. If not treated, most babies die within a few months.

TREATMENT OPTIONS

- Your doctor will work with a metabolic specialist and dietician to care for your child.
- In addition to a low-protein diet, children are often given a special medical formula as a substitute for milk. This formula gives them the nutrients and protein they need.
- Diet low in branched-chain amino acids (BCAA)-The diet is made up of foods that are very low in the BCAAs. This means your child will need to avoid foods such as cow's milk, regular formula, meat, fish, cheese and eggs. Regular flour, dried beans, nuts, and peanut butter also have BCAAs and must be avoided or strictly limited. Many vegetables and fruits have only small amounts of the BCAAs and can be eaten in carefully measured amounts.
- Your child will have regular blood tests to measure amino acid levels. The diet and formula may need to be adjusted based on blood test results.
- Children with a rare form of MSUD, called "thiamine-responsive MSUD", can often be helped by thiamine supplements. Do not use any supplements without checking with your doctor.
- Call your doctor at the start of any illness. For children with MSUD, even minor illness can cause a metabolic crisis.

IF TREATED

With prompt and lifelong treatment, children with MSUD often have healthy lives with typical growth and development. Early treatment can help prevent brain damage and mental retardation. Even with treatment, some children still develop swelling of the brain or have episodes of metabolic crisis. Children who have repeated metabolic crises may develop permanent brain damage. This can cause lifelong learning problems, mental retardation or spasticity.

12/1/05 Update

For more information go to the following website: http://chfs.ky.gov/dph/ach/ecd/newbornscreening.htm
PARENT FACT SHEET

DISORDER

Medium-chain acyl-CoA dehydrogenase deficiency (MCAD)

CAUSE

MCAD occurs when an enzyme called “medium chain acyl-CoA dehydrogenase” is either missing or not working properly. This enzyme’s job is to break down certain fats in the food we eat into energy. It also breaks down fat already stored in the body. Energy from fat keeps us going whenever our bodies run low of their main source of energy, a type of sugar called glucose. Our bodies rely on fat when we don’t eat for a period of time.

IF NOT TREATED

When the MCAD enzyme is missing or not working, the body cannot use certain types of fat for energy and must rely solely on glucose. Although glucose is a good source of energy, there is a limited amount available. Once the glucose has been used up, the body tries to use fat without success. This leads to low blood sugar, called hypoglycemia, and to the build of harmful substances in the blood. This is called a metabolic crisis. Metabolic crisis can cause permanent brain damage and even death.

TREATMENT OPTIONS

Your child will need to be under the care of a metabolic specialist and dietician. Treatment is usually needed throughout life.

- Your child needs to avoid going a long time without food. This is to avoid a metabolic crisis. These children should not go more than 4 to 6 hours without food and some may require more frequent feedings. It is important that these children be fed in the night – meaning you will need to wake them up to eat if they do not wake up on their own – and even if they are not hungry.
- Your metabolic specialist and dietician will design a low-fat, high carbohydrate diet for your child. This may include a special formula when your child is an infant. No changes in diet can happen without first getting permission from the metabolic specialist and dietician.
- Some children may benefit from taking L-carnitine. This is a safe and natural substance that helps the body make energy. The metabolic specialist will decide if your child can benefit from this treatment. A prescription for this is required.
- Contact your child’s doctor immediately at the start of any illness. Children with MCAD need to be treated in a hospital to prevent serious health problems.

IF TREATED

With prompt and careful treatment, children with MCAD usually live health lives with typical growth and development. The goal of treatment is to prevent long-term problems. However, children who have repeated metabolic crises may have life-long learning disabilities, uncontrolled movements in their muscles and tendons, or other effects.

12/1/05 Update

For more information go to the following website: http://chfs.ky.gov/dph/ach/ecd/newbornscreening.htm
Parent Fact Sheet

**DISORDER**

Methylmalonic Acidemia (Cbl A, B)

**CAUSE**

MMA stands for "methylmalonic acidemia". It is one type of organic acid disorder. People with MMA have problems breaking down and using certain amino acids and fatty acids from the food they eat.

**IF NOT TREATED**

MMA causes episodes of illness called metabolic crises. A metabolic crisis can cause harmful substances from the body to spill into the blood and urine.

If a metabolic crisis is not treated, a child with MMA can develop breathing problems, seizures, stroke and coma, sometimes leading to death. A metabolic crisis can be triggered by eating large amounts of protein, illness or infection, going too long without food, and stressful events such as surgery. Without treatment, brain and nerve damage can occur. This can cause mental retardation and problems with involuntary movements of the muscles and tendons. Death is common in untreated babies and children.

**TREATMENT OPTIONS**

- Your baby's primary doctor will work with a metabolic doctor and a dietician to care for your child. Prompt treatment is needed to reduce the chance for mental retardation and serious medical problems.
- Children with 'vitamin B12 responsive' MMA are given vitamin B12.
- Most children need to be on a low-protein diet and drink a special medical formula. You should start the treatments as soon as you know your child has MMA.
- Children who are having symptoms of a metabolic crisis should be treated in the hospital. During a metabolic crisis, your child may be given medications such as bicarbonate through an IV to help reduce the acid levels in the blood. Glucose is given by IV to prevent the breakdown of protein and fat stored in the body. Do not use any medication without checking with your doctor.
- A food plan low in the amino acids leucine, valine, methionine, and threonine with limited amounts of protein is often recommended. Most food in the diet will be carbohydrates (bread, cereal, pasta, fruit, vegetables, etc.). Carbohydrates give the body many types of sugar that can be used as energy. Eating a diet high in carbohydrates and low in protein and fat can help prevent metabolic crises. Your dietician can create a food plan that contains the right amount of protein, nutrients, and energy to keep your child healthy. It is likely your child will need to be on a special food plan throughout life.
- Contact your child's doctor immediately at the start of any illness.

**IF TREATED**

Babies and children who have prompt and ongoing treatment may be able to live healthy lives with normal growth and development. In general, the earlier treatment is started, the better the outcome. Children who respond to vitamin B12 treatment tend to do very well as long as treatment is continued. Children who are not treated until after they have symptoms may have lasting health and learning problems. Even with treatment, some children develop life-long learning disabilities or mental retardation. In addition, despite treatment, seizures, involuntary movement disorders, and kidney failure have occurred in some children.

12/1/05 Update

For more information go to the following website: [http://chfs.ky.gov/dph/ach/ecd/newbornscreening.htm](http://chfs.ky.gov/dph/ach/ecd/newbornscreening.htm)
Parent Fact Sheet

DISORDER
Methylmalonic Acidemia Mutase Deficiency (MUT)

CAUSE
MMA stands for "methylmalonic acidemia". It is one type of organic acid disorder. People with MMA have problems breaking down and using certain amino acids and fatty acids from the food they eat.

IF NOT TREATED
MMA causes episodes of illness called metabolic crises. A metabolic crisis can cause harmful substances from the body to spill into the blood and urine. If a metabolic crisis is not treated, a child with MMA can develop breathing problems, seizures, stroke and coma, sometimes leading to death. A metabolic crisis can be triggered by eating large amounts of protein, illness or infection, going too long without food and stressful events such as surgery. Without treatment, brain and nerve damage can occur. This can cause mental retardation and problems with involuntary movements. Death is common in untreated babies and children.

TREATMENT OPTIONS
• Your baby's primary doctor will work with a metabolic doctor and a dietician to care for your child. Prompt treatment is needed to reduce the chance for mental retardation and serious medical problems. Children with 'vitamin B12 responsive' MMA are given vitamin B12. In addition, most children need to be on a low-protein diet and drink a special medical formula. You should start the treatments as soon as you know your child has MMA.
• Children who are having symptoms of a metabolic crisis should be treated in the hospital. During a metabolic crisis, your child may be given medications such as bicarbonate through an IV to help reduce the acid levels in the blood. Glucose is given by IV to prevent the breakdown of protein and fat stored in the body. Do not use any medication without checking with your doctor.
• A food plan low in the amino acids leucine, valine, methionine, and threonine with limited amounts of protein is often recommended. Most food in the diet will be carbohydrates (bread, cereal, pasta, fruit, vegetables, etc.). Carbohydrates give the body many types of sugar that can be used as energy. Eating a diet high in carbohydrates and low in protein and fat can help prevent metabolic crises.
• Your dietician can create a food plan that contains the right amount of protein, nutrients, and energy to keep your child healthy. It is likely your child will need to be on a special food plan throughout life.

IF TREATED
Babies and children who have prompt and ongoing treatment may be able to live healthy lives with normal growth and development. In general, the earlier treatment is started, the better the outcome. Children who respond to vitamin B12 treatment tend to do very well as long as treatment is continued. Children who are not treated until after they have symptoms may have lasting health and learning problems. Even with treatment, some children develop life-long learning disabilities or mental retardation. In addition, despite treatment, seizures, involuntary movement disorders, and kidney failure have occurred in some children.

12/1/05 Update

For more information go to the following website: http://chfs.ky.gov/dph/ach/ecd/newbornscreening.htm
PARENT FACT SHEET

DISORDER

Multiple carboxylase deficiency (MCD)

CAUSE

MCD occurs when an enzyme called “holocarboxylase synthetase” (HCS) is either missing or not working properly. This enzyme’s job is to add a vitamin called “biotin” to other enzymes called “carboxylases” so that they can change the food we eat into energy for the body. When the HCS enzyme is not working certain harmful substances build up in the blood and urine. This can cause serious health problems.

IF NOT TREATED

Each child with MCD is likely to have slightly different effects. Many babies with this condition start to have symptoms within hours of birth or during the first few days or weeks of life. Other babies have their first symptoms sometime in infancy, usually before two years of age. Without treatment, brain damage can occur. This can result in mental retardation or, sometimes, even death.

TREATMENT OPTIONS

Your child will need to be under the care of a metabolic specialist. Treatment is needed throughout life.

- The main treatment for MCD is a type of vitamin B called “biotin.” In babies found to have MCD through newborn screening, biotin treatment can prevent symptoms from occurring. It can also reverse some of the health problems in children who have already shown symptoms.
- You will need a prescription from the metabolic specialist for biotin. They will determine the proper amount your child needs to take.
- Contact your child’s doctor immediately at the start of any illness

IF TREATED

Babies who receive prompt and ongoing treatment with biotin before they have a metabolic crisis are expected to have normal growth and development. Even with treatment, a few children have developed lifelong learning problems or mental retardation. In children who have already show delays in learning, or a loss of hearing or eyesight, treatment can prevent additional effects. But it may not be able to correct the effects that are already present.

For more information go to the following website: http://chfs.ky.gov/dph/ach/ecd/newbornscreening.htm
Parent Fact Sheet

DISORDER

Phenylketonuria (PKU)

CAUSE

PKU is one type of amino acid disorder. People with PKU have trouble breaking down an amino acid called phenylalanine from the food they eat. PKU occurs when an enzyme called “phenylalanine hydroxylase” is either missing or not working properly. This enzyme’s job is to break down the amino acid phenylalanine. When a child with PKU eats foods with phenylalanine, it builds up in the blood and causes problems. It is found in almost every food, except pure fat and sugar.

IF NOT TREATED

The symptoms can vary from person to person. Babies with PKU seem perfectly normal at birth. The first effects are usually seen around 6 months of age. Untreated infants may be late learning to sit, crawl, and stand. They may pay less attention to things around them. Without treatment, a child with PKU will become mentally retarded.

Some of the effects of untreated PKU are: mental retardation, behavioral problems, hyperactivity, restlessness or irritability, seizures, eczema, musty or mousy body odor, fair hair and skin.

TREATMENT OPTIONS

- Your doctor will work with a metabolic specialist and dietician to care for your child. Lifelong treatment is usually needed.
- Prompt treatment is needed to prevent mental retardation. Newborns need to drink a special medical formula. It is possible to still breastfeed your baby as long as you get help from a dietician. Babies who are breastfed usually need the medical formula as well.
- A diet low in phenylalanine (Phe) is generally prescribed. Your child must not have cow’s milk, regular formula, meat, fish, eggs or cheese. You must avoid the sugar substitute aspartame (Equal, NutraSweet) because it contains high levels of phenylalanine and can quickly raise the blood levels of Phe in people with PKU.
- Blood levels with have to be checked regularly to monitor the levels of PHE. The diet and formula may have to be adjusted.
- Contact your child’s doctor immediately at the start of any illness

IF TREATED

Children who receive early treatment and keep their Phe levels within the suggested ranges may be able to live healthy lives with typical growth and development. Some children may continue to have learning difficulties and other health problems despite treatment. If treatment is not started until 6 months of age, mental retardation often occurs. Treatment, even if started late, can help control behavior and mood problems and further prevent damage to the brain.

12/1/05 Update

For more information go to the following website: http://chfs.ky.gov/dph/ach/ecd/newbornscreening.htm
Parent Fact Sheet

DISORDER

Propionic Acidemia (PA)

CAUSE

Propionic Acidemia (PA) is one type of organic acid disorder. People with PA have problems breaking down and using certain amino acids from the foods they eat. PA occurs when an enzyme called “propionyl CoA carboxylase” is either missing or not working properly. When this enzyme is not working, substances called glycine and propionic acid along with other harmful substances build up in the blood and cause problems.

IF NOT TREATED

The symptoms can start as early as the first week of life. If untreated, harmful substances from the body spill into the blood and urine. This is called a metabolic acidosis. If a metabolic crisis is not treated, a child with PA can develop breathing problems, stroke, swelling of the brain, seizures and coma - sometimes leading to death.

A metabolic crisis can be triggered by eating large amounts of protein, illness or infection, going to long without food, and stressful events such as surgery.

TREATMENT OPTIONS

- Your doctor will work with a metabolic specialist and dietician to care for your child. Lifelong treatment is usually needed.
- Avoid going a long time without food. These babies need to eat more often to avoid low blood sugar. They should not go without eating for more than 4-6 hours. Some babies will need to eat more often than this.
- A low protein diet is often recommended. Your dietician will help plan any diet changes.
- Medical formula and foods contain the correct amount of protein and nutrients needed to for normal growth and development. Your metabolic doctor will tell you what type of formula is best and how much to use.
- A medication that has been found to be beneficial is L-Carnitine. It is a safe and natural substance that helps the body create energy and rid the body of harmful wastes. Unless you are advised otherwise, use only L-Carnitine prescribed by your doctor. Some children may be prescribed Biotin supplements, which is a type of B vitamin.
- Contact your child’s doctor immediately at the start of any illness

IF TREATED

It is not known how effective treatment is in preventing problems. Children who are treated early may be able to live healthy lives with typical growth and development. Some children may continue to have seizures, mental retardation, involuntary movements and other health problems despite treatment.

12/1/05 Update

For more information go to the following website: http://chfs.ky.gov/dph/ach/ecd/newbornscreening.htm
Parent Fact Sheet

DISORDER

Short Chain Acyl-CoA Dehydrogenase Deficiency (SCAD)

CAUSE

People with Short Chain Acyl-CoA Dehydrogenase (SCAD) deficiency have problems breaking down fat into energy for their body. Most babies with newborn screening results showing SCAD never have symptoms. It occurs when an enzyme called "short chain Acyl-CoA dehydrogenase" is either missing or not working properly. It also breaks down fat already stored in the body.

Energy from fat keeps us going whenever our bodies run out of the main source of energy glucose. Our bodies rely on fat when we do not eat for a stretch of time-like sleeping during the night or missing a meal. Some people with SCAD cannot break down fat for energy. However, most people with SCAD do not seem to have this problem and do not ever develop symptoms.

IF NOT TREATED

The symptoms can start as early as the first week of life. If untreated, harmful substances from the body spill into the blood and urine. This is called a metabolic crisis. If a metabolic crisis is not treated, a child with SCAD can develop breathing problems, seizures and coma - sometimes leading to death.

TREATMENT OPTIONS

• Your doctor will work with a metabolic specialist and dietician to care for your child. Lifelong treatment is usually needed.
• Avoid going a long time without food. These babies need to eat more often to avoid low blood sugar. They should not go without eating for more than 4-6 hours. Some babies will need to eat more often than this.
• A low fat, high carbohydrate diet is often recommended. Your dietician will help plan any diet changes.
• L-Carnitine and Riboflavin may be prescribed by your doctor. L-Carnitine is a safe and natural substance that helps the body create energy and rid the body of harmful wastes. Riboflavin is vitamin B2 and a few children have been helped by taking it.
• Contact your child’s doctor immediately at the start of any illness

IF TREATED

It is not known how effective treatment is in preventing problems. Children who are treated early may be able to live healthy lives with typical growth and development. Some children may continue to have learning delays, muscle weakness and other health problems despite treatment.

12/1/05 Update

For more information go to the following website: http://chfs.ky.gov/dph/ach/ecd/newbornscreening.htm
Parent Fact Sheet

DISORDER

Sickle Cell Disease (HB S/S)

CAUSE

Sickle cell disease is an inherited blood disorder that affects red blood cells. People with sickle cell disease have red blood cells that contain mostly hemoglobin S, an abnormal type of hemoglobin.

People with sickle cell conditions make a different form of hemoglobin called hemoglobin S (S stands for sickle). Red blood cells containing mostly hemoglobin S do not live as long as normal red blood cells (normally about 16 days). They also become stiff, distorted in shape and have difficulty passing through the body’s small blood vessels. When sickle-shaped cells block small blood vessels, less blood can reach that part of the body. Tissue that does not receive a normal blood flow eventually becomes damaged. This is what causes the complications of sickle cell disease.

IF NOT TREATED

Untreated newborns often develop septicemia, an infection of the blood, and die within a few weeks of birth.

The leading cause of death in children with sickle cell disease in the United States is infection. The most troublesome germ is pneumococcus.

TREATMENT OPTIONS

- Health maintenance for patients with sickle cell disease starts with early diagnosis, preferably in the newborn period and includes penicillin prophylaxis, vaccination against pneumococcus bacteria and folic acid supplementation.
- Treatment of complications often includes: antibiotics, pain management, intravenous fluids, blood transfusion and surgery.
- Contact your child’s doctor immediately at the start of any illness

IF TREATED

Treatment for the symptoms of sickle cell disease has improved over the years and many people with sickle cell disease are living longer.

12/1/05 Update

For more information go to the following website: http://chfs.ky.gov/dph/ach/ecd/newbornscreening.htm
DISORDER

Trifunctional Protein Deficiency (TFP)

CAUSE

People with trifunctional protein (TFP) deficiency have problems breaking down fat into energy for their body. TFP deficiency occurs when a group of enzymes, called “trifunctional protein” is either missing or not working properly. The job of TFP is to breakdown certain fats from the food we eat into energy. It also breaks down fat already stored in the body.

Energy from fat keeps us going whenever our bodies run out of the main source of energy glucose. Our bodies rely on fat when we do not eat for a stretch of time-like sleeping during the night or missing a meal. When TFP is missing or not working well, the body cannot use fats for energy. Once all the glucose is used up, the body tries to use fat without success. This leads to low blood sugar and to the buildup of harmful substances in the blood.

IF NOT TREATED

The symptoms can vary from person to person. Babies with early TFP deficiency have episodes of illness called metabolic crisis. If untreated, harmful substances from the body spill into the blood and urine. This is called a metabolic crisis. If a metabolic crisis is not treated, a child with TFP deficiency can develop breathing problems, seizures, and coma - sometimes leading to death.

TREATMENT OPTIONS

- Your doctor will work with a metabolic specialist and dietician to care for your child. Lifelong treatment is usually needed.
- Avoid going a long time without food. These babies need to eat more often to avoid low blood sugar. They should not go without eating for more than 4-6 hours. Some babies will need to eat more often than this.
- A low fat, high carbohydrate diet is often recommended. Your dietician will help plan any diet changes.
- Medium Chain Triglyceride oil (MCT) and L-Carnitine is often used as part of the food plan for people with TFP deficiency. This special oil has medium chain fatty acids that can be used in small amounts for energy. You dietician will tell you how to use this supplement. You will have to get a prescription from the doctor for MCT oil.
- Contact your child’s doctor immediately at the start of any illness

IF TREATED

Babies with TFP who receive treatment may have a prolonged life expectancy than without treatment.

12/1/05 Update

For more information go to the following website: http://chfs.ky.gov/dph/ach/ecd/newbornscreening.htm
Tyrosinemia, type 1 (TYR I)

CAUSE

People with tyrosinemia 1 have problems breaking down an amino acid called tyrosine from the food they eat. In order for the body to use protein from the food we eat, it is broken down into smaller parts called amino acids. Special enzymes then make changes to the amino acids so the body can use them. Tyrosinemia 1 occurs when an enzyme called fumarylacetoacetase (FAH) is either missing or not working properly.

IF NOT TREATED

The symptoms can vary from person to person. Children with TYR 1 usually smell like cabbage. Babies usually will have symptoms within the first few months of life. Without prompt and careful treatment, babies with severe liver and kidney problems usually die.

TREATMENT OPTIONS

- Your doctor will work with a metabolic specialist and dietician to care for your child. Lifelong treatment is usually needed to prevent liver and kidney problems.
- A medication called nitisinone (Orfadin®) is used to prevent liver and kidney damage. Your child should take this medication as soon as possible. Nitisinone will increase the level of tyrosine in your child’s blood.
- Also a low tyrosine and low phenylalanine diet is very important. Your baby will have to avoid cow’s milk, regular formula, meats, eggs and cheeses. A special formula will be ordered for your baby so they will get those nutrients and protein they will need to keep their levels within a safe range.
- Your child will have regular visits to the doctor as well as regular blood tests to see if there should be any changes to the medication. Contact your child’s doctor immediately at the start of any illness.
- Liver transplant may be an option to prevent liver cancer.

IF TREATED

Children who are treated early usually live healthy lives with typical growth and development. When treatment is started early, severe kidney and neurologic symptoms can be prevented. If treatment is not started right away, liver and kidney damage may occur. Delays in growth and development may also be present.

For more information go to the following website: http://chfs.ky.gov/dph/ach/ecd/newbornscreening.htm

12/1/05 Update
PARENT FACT SHEET

DISORDER

Very long-chain acyl-CoA dehydrogenase deficiency (VLCAD)

CAUSE

VLCAD occurs when the very long chain acyl-CoA dehydrogenase enzyme is missing or not working properly. This enzyme’s job is to break down certain fats from the food we eat into energy. It also breaks down fat already stored in the body.

IF NOT TREATED

VLCAD is variable and can cause mild effects in some people and more serious health problems in others. Symptoms may start in infancy or not until adulthood. There are three forms of VLCAD: Early, Childhood, and Adult.

TREATMENT OPTIONS

Your child will need to be under the care of a metabolic specialist and dietician. Treatment is usually needed throughout life.

- Your child needs to avoid going a long time without food. This is to prevent a rapid drop in blood sugar. These children should not go more than 4 to 6 hours without food and some may require more frequent feedings. It is important that these children be fed in the night – meaning you will need to be wake them up to eat if they do not wake up on their own – even if they are not hungry.
- Frequently, a low fat, high carbohydrate diet is recommended. Your dietician will help develop your child’s food plan and no changes should be made without first getting the approval of the metabolic specialist and the dietician.
- Medium Chain Triglyceride oil (MCT oil) is often used as part of the child’s food plan. You will require a prescription from the metabolic specialist to get this. The specialist and the dietician will assist you in how to properly use MCT oil.
- Some children take L-carnitine. It is a safe and natural substance that helps the body make energy. The metabolic specialist will decide if your child can benefit from this treatment. A prescription for this is also required.
- Contact your child’s doctor immediately at the start of any illness. Children with VLCAD need to be treated in a hospital to prevent serious health problems.
- Avoid your child’s prolonged exercise or exertion.

IF TREATED

Before diagnosis through newborn screening was possible, the early form of VLCAD was fatal. Now, with immediate and ongoing treatment, many infants are surviving. With prompt and careful treatment, people with childhood and adult forms of VLCAD can often live healthy lives with typical growth and development.

12/1/05 Update

For more information go to the following website: http://chfs.ky.gov/dph/ach/ecd/newbornscreening.htm
Action Sheets-

By following the link below you can find the Action Sheets to each of the 29 disorders we screen for:

http://chfs.ky.gov/dph/ach/ecd/newbornscreening.htm

Once you get to the website, scroll down to where you see Parent Information Sheets and then below those are the Health Care Providers Fact Sheets.
The American College of Medical Genetics evaluated conditions for inclusion in newborn screening and has made recommendations, the following pages are conditions that were considered but not included in the final recommendation.

To be included as a primary target condition in a newborn screening program, a condition should meet the following minimum criteria:

- It can be identified at a phase (24 to 48 hours after birth) at which it would not ordinarily be clinically detected;
- A test with appropriate sensitivity and specificity is available for it;
- There are demonstrated benefits of early detection, timely intervention and efficacious treatment of the condition being tested.
## Disorders Considered by American College of Medical Genetics for Newborn Screening But Not on Current Panel

<table>
<thead>
<tr>
<th>Condition</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>2-Methyl 3-hydroxy butyric aciduria</td>
<td>2M3HBA</td>
</tr>
<tr>
<td>2-Methylbutyryl-CoA dehydrogenase deficiency</td>
<td>2MBG</td>
</tr>
<tr>
<td>3-Methylglutaconic aciduria</td>
<td>3MGA</td>
</tr>
<tr>
<td>Adenosine deaminase deficiency</td>
<td>ADA</td>
</tr>
<tr>
<td>Arginine: glycine amidinotransferase deficiency</td>
<td>AGAT</td>
</tr>
<tr>
<td>Argininemia</td>
<td>ARG</td>
</tr>
<tr>
<td>Benign Hyperphenylalaninemia</td>
<td>H-PHE</td>
</tr>
<tr>
<td>Biliary atresia</td>
<td>BIL</td>
</tr>
<tr>
<td>Carbamylphosphate synthetase deficiency</td>
<td>CPS</td>
</tr>
<tr>
<td>Carnitine palmitoyltransferase Ia deficiency (L)</td>
<td>CPT IA</td>
</tr>
<tr>
<td>Carnitine palmitoyltransferase Ib deficiency (M)</td>
<td>CPT IB</td>
</tr>
<tr>
<td>Carnitine palmitoyltransferase II deficiency</td>
<td>CPTII</td>
</tr>
<tr>
<td>Carnitine/acylcarnitine translocase deficiency</td>
<td>CACT</td>
</tr>
<tr>
<td>Citrullinemia type II</td>
<td>CIT II</td>
</tr>
<tr>
<td>Congenital Cytomegalovirus infection</td>
<td>CMV</td>
</tr>
<tr>
<td>Congenital disorder of glycosylation type Ib</td>
<td>CDG Ib</td>
</tr>
<tr>
<td>Congenital Toxoplasmosis</td>
<td>TOXO</td>
</tr>
<tr>
<td>Creatine transporter defect</td>
<td>CR TRANS</td>
</tr>
<tr>
<td>Defects of biopterin cofactor biosynthesis</td>
<td>BIOPT BS</td>
</tr>
<tr>
<td>Defects of biopterin cofactor regeneration</td>
<td>BIOPT REG</td>
</tr>
<tr>
<td>Diabetes mellitus, insulin dependent</td>
<td>IDDM</td>
</tr>
<tr>
<td>Dienoyl-CoA reductase deficiency</td>
<td>DE-RED</td>
</tr>
<tr>
<td>Duchenne and Becker Muscular Dystrophy</td>
<td>DMD</td>
</tr>
<tr>
<td>Fabry disease</td>
<td>FABRY</td>
</tr>
<tr>
<td>Familial hypercholesterolemia (heterozygote)</td>
<td>FHC</td>
</tr>
<tr>
<td>Fragile X</td>
<td>FX</td>
</tr>
<tr>
<td>Galactokinase deficiency</td>
<td>GALK</td>
</tr>
<tr>
<td>Galactose epimerase deficiency</td>
<td>GALE</td>
</tr>
<tr>
<td>Glucose-6-phosphate dehydrogenase deficiency</td>
<td>G6PD</td>
</tr>
<tr>
<td>Glutaric acidemia type II</td>
<td>GA2</td>
</tr>
<tr>
<td>Guanidinoacetate methyltransferase deficiency</td>
<td>GAMT</td>
</tr>
<tr>
<td>Human HIV infection</td>
<td>HIV</td>
</tr>
<tr>
<td>Hurler-Scheie disease</td>
<td>MPS-1H</td>
</tr>
<tr>
<td>Condition</td>
<td>Code</td>
</tr>
<tr>
<td>------------------------------------------------------------</td>
<td>----------</td>
</tr>
<tr>
<td>Hyperbilirubinemia*</td>
<td>HPRBIL</td>
</tr>
<tr>
<td>Hypermethioninemia</td>
<td>MET</td>
</tr>
<tr>
<td>Isobutyryl-CoA dehydrogenase deficiency</td>
<td>IBG</td>
</tr>
<tr>
<td>Krabbe disease</td>
<td>KRABBE</td>
</tr>
<tr>
<td>Lysosomal storage diseases</td>
<td>LSD</td>
</tr>
<tr>
<td>Malonic aciduria</td>
<td>MAL</td>
</tr>
<tr>
<td>Medium chain ketoacyl-CoA thiolase deficiency</td>
<td>MCKAT</td>
</tr>
<tr>
<td>Medium/short-chain 3-OH acyl-CoA DH def.</td>
<td>M/SCHAD</td>
</tr>
<tr>
<td>Methylmalonic acidemia (Cbl C,D)</td>
<td>Cbl C,D</td>
</tr>
<tr>
<td>Neuroblastoma</td>
<td>NB</td>
</tr>
<tr>
<td>Ornithine transcarbamylase deficiency</td>
<td>OTC</td>
</tr>
<tr>
<td>Other variant Hb-pathies (including Hb E)</td>
<td>Var Hb</td>
</tr>
<tr>
<td>Pompe disease</td>
<td>POMPE</td>
</tr>
<tr>
<td>Severe combined immunodeficiency</td>
<td>SCID</td>
</tr>
<tr>
<td>Smith-Lemli-Opitz syndrome</td>
<td>SLO</td>
</tr>
<tr>
<td>Turner syndrome</td>
<td>TURNER</td>
</tr>
<tr>
<td>Tyrosinemia type II</td>
<td>TYR II</td>
</tr>
<tr>
<td>Tyrosinemia type III</td>
<td>TYR III</td>
</tr>
<tr>
<td>Wilson disease</td>
<td>WD</td>
</tr>
<tr>
<td>X-linked Adrenoleukodystrophy</td>
<td>ALD</td>
</tr>
<tr>
<td>α1-Antitrypsin deficiency</td>
<td>α1AT</td>
</tr>
</tbody>
</table>
## Index to Diseases

<table>
<thead>
<tr>
<th>Condition</th>
<th>Code</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>2-Methyl 3-hydroxy butyric aciduria</td>
<td>2M3HBA</td>
<td>10B</td>
</tr>
<tr>
<td>2-Methylbutyryl-CoA dehydrogenase deficiency</td>
<td>2MBG</td>
<td>10B</td>
</tr>
<tr>
<td>3-hydroxy 3-methyl glutaric aciduria</td>
<td>HMG</td>
<td>8AC-8AD</td>
</tr>
<tr>
<td>3-Methylcrotonyl-CoA carboxylase deficiency</td>
<td>3MCC</td>
<td>8A-8B</td>
</tr>
<tr>
<td>3-Methylglutaconic aciduria</td>
<td>3MGA</td>
<td>10B</td>
</tr>
<tr>
<td>Adenosine deaminase deficiency</td>
<td>ADA</td>
<td>10B</td>
</tr>
<tr>
<td>Arginine: glycine amidinotransferase deficiency</td>
<td>AGAT</td>
<td>10B</td>
</tr>
<tr>
<td>Argininemia</td>
<td>ARG</td>
<td>10B</td>
</tr>
<tr>
<td>Argininosuccinic acidemia</td>
<td>ASA</td>
<td>8C-8D</td>
</tr>
<tr>
<td>Benign Hyperphenylalaninemia</td>
<td>H-PHE</td>
<td>10B</td>
</tr>
<tr>
<td>Beta-Ketothiolase deficiency</td>
<td>βKT</td>
<td>8E-8F</td>
</tr>
<tr>
<td>Biliary atresia</td>
<td>BIL</td>
<td>10B</td>
</tr>
<tr>
<td>Biotinidase deficiency</td>
<td>BIOT</td>
<td>8G-8H</td>
</tr>
<tr>
<td>Carbamylphosphate synthetase deficiency</td>
<td>CPS</td>
<td>10B</td>
</tr>
<tr>
<td>Carnitine palmitoyltransferase Ia deficiency (L)</td>
<td>CPT IA</td>
<td>10B</td>
</tr>
<tr>
<td>Carnitine palmitoyltransferase Ib deficiency (M)</td>
<td>CPT IB</td>
<td>10B</td>
</tr>
<tr>
<td>Carnitine palmitoyltransferase II deficiency</td>
<td>CPTII</td>
<td>10B</td>
</tr>
<tr>
<td>Carnitine uptake defect</td>
<td>CUD</td>
<td>8I-8J</td>
</tr>
<tr>
<td>Carnitine/acylcarnitine translocase deficiency</td>
<td>CACT</td>
<td>10B</td>
</tr>
<tr>
<td>Citrullinemia</td>
<td>CIT</td>
<td>8K-8L</td>
</tr>
<tr>
<td>Citrullinemia type II</td>
<td>CIT II</td>
<td>10B</td>
</tr>
<tr>
<td>Classic galactosemia</td>
<td>GALT</td>
<td>8S-8T</td>
</tr>
<tr>
<td>Congenital adrenal hyperplasia</td>
<td>CAH</td>
<td>8M-8N</td>
</tr>
<tr>
<td>Congenital Cytomegalovirus infection</td>
<td>CMV</td>
<td>10B</td>
</tr>
<tr>
<td>Congenital disorder of glycosylation type Ib</td>
<td>CDG Ib</td>
<td>10B</td>
</tr>
<tr>
<td>Congenital hypothyroidism</td>
<td>CH</td>
<td>8O-8P</td>
</tr>
<tr>
<td>Congenital Toxoplasmosis</td>
<td>TOXO</td>
<td>10B</td>
</tr>
<tr>
<td>Creatine transporter defect</td>
<td>CR TRANS</td>
<td>10B</td>
</tr>
<tr>
<td>Cystic fibrosis</td>
<td>CF</td>
<td>8Q-8R</td>
</tr>
<tr>
<td>Defects of biopterin cofactor biosynthesis</td>
<td>BIOPT BS</td>
<td>10B</td>
</tr>
<tr>
<td>Defects of biopterin cofactor regeneration</td>
<td>BIOPT REG</td>
<td>10B</td>
</tr>
<tr>
<td>Condition</td>
<td>Code</td>
<td>Page #</td>
</tr>
<tr>
<td>---------------------------------------------------------------------------</td>
<td>-----------</td>
<td>---------</td>
</tr>
<tr>
<td>Diabetes mellitus, insulin dependent</td>
<td>IDDM</td>
<td>10B</td>
</tr>
<tr>
<td>Dienoyl-CoA reductase deficiency</td>
<td>DE-RED</td>
<td>10B</td>
</tr>
<tr>
<td>Duchenne and Becker Muscular Dystrophy</td>
<td>DMD</td>
<td>10B</td>
</tr>
<tr>
<td>Fabry disease</td>
<td>FABRY</td>
<td>10B</td>
</tr>
<tr>
<td>Familial hypercholesterolemia (heterozygote)</td>
<td>FHC</td>
<td>10B</td>
</tr>
<tr>
<td>Fragile X</td>
<td>FX</td>
<td>10B</td>
</tr>
<tr>
<td>Galactokinase deficiency</td>
<td>GALK</td>
<td>10B</td>
</tr>
<tr>
<td>Galactose (Classic)</td>
<td>GALT</td>
<td>8S-8T</td>
</tr>
<tr>
<td>Galactose epimerase deficiency</td>
<td>GALE</td>
<td>10B</td>
</tr>
<tr>
<td>Glucose-6-phosphate dehydrogenase deficiency</td>
<td>G6PD</td>
<td>10B</td>
</tr>
<tr>
<td>Glutaric acidemia type I</td>
<td>GA I</td>
<td>8U-8V</td>
</tr>
<tr>
<td>Glutaric acidemia type II</td>
<td>GA2</td>
<td>10B</td>
</tr>
<tr>
<td>Guanidinoacetate methyltransferase deficiency</td>
<td>GAMT</td>
<td>10B</td>
</tr>
<tr>
<td>Hearing loss</td>
<td>HEAR</td>
<td>6E</td>
</tr>
<tr>
<td>Hemoglobin S/β-thalassemia</td>
<td>Hb S/βThal</td>
<td>8W-8X</td>
</tr>
<tr>
<td>Hemoglobin S/C disease</td>
<td>Hb S/C</td>
<td>8Y-8Z</td>
</tr>
<tr>
<td>Hemoglobin SS disease (Sickle cell anemia)</td>
<td>Hb SS</td>
<td>8AY-8AZ</td>
</tr>
<tr>
<td>Homocystinuria</td>
<td>HCY</td>
<td>8AA-8AB</td>
</tr>
<tr>
<td>Human HIV infection</td>
<td>HIV</td>
<td>10B</td>
</tr>
<tr>
<td>Hurler-Scheie disease</td>
<td>MPS-IH</td>
<td>10B</td>
</tr>
<tr>
<td>Hydroxymethylglutaric aciduria</td>
<td>HMG</td>
<td>8AC-8AD</td>
</tr>
<tr>
<td>Hyperbilirubinemia</td>
<td>HPRBIL</td>
<td>10B</td>
</tr>
<tr>
<td>Hypermethioninemia</td>
<td>MET</td>
<td>10C</td>
</tr>
<tr>
<td>Isobutyryl-CoA dehydrogenase deficiency</td>
<td>IBG</td>
<td>10C</td>
</tr>
<tr>
<td>Isovaleric acidemia</td>
<td>IVA</td>
<td>8AE-8AF</td>
</tr>
<tr>
<td>Krabbe disease</td>
<td>KRABBE</td>
<td>10C</td>
</tr>
<tr>
<td>Long-chain 3-OH acyl-CoA dehydrogenase def.</td>
<td>LCHAD</td>
<td>8AG-8AH</td>
</tr>
<tr>
<td>Lysosomal storage diseases</td>
<td>LSD</td>
<td>10C</td>
</tr>
<tr>
<td>Malonic aciduria</td>
<td>MAL</td>
<td>10C</td>
</tr>
<tr>
<td>Maple syrup (urine) disease</td>
<td>MSUD</td>
<td>9AI-8AJ</td>
</tr>
<tr>
<td>Medium chain ketoacyl-CoA thiolase deficiency</td>
<td>MCKAT</td>
<td>10C</td>
</tr>
<tr>
<td>Medium/short-chain 3-OH acyl-CoA DH def.</td>
<td>M/SCHAD</td>
<td>10C</td>
</tr>
<tr>
<td>Medium-chain acyl-CoA dehydrogenase deficiency</td>
<td>MCAD</td>
<td>8AK-8AL</td>
</tr>
<tr>
<td>Methylmalonic acidemia (Cbl A, B)</td>
<td>Cbl A,B</td>
<td>8AM-8AN</td>
</tr>
<tr>
<td>Condition</td>
<td>Code</td>
<td>Page #</td>
</tr>
<tr>
<td>----------------------------------------------------</td>
<td>----------</td>
<td>--------</td>
</tr>
<tr>
<td>Methylmalonic acidemia (Cbl C,D)</td>
<td>Cbl C,D</td>
<td>10C</td>
</tr>
<tr>
<td>Methylmalonic acidemia (mutase)</td>
<td>MUT</td>
<td>8AO-8AP</td>
</tr>
<tr>
<td>Multiple carboxylase deficiency</td>
<td>MCD</td>
<td>8AQ-8AR</td>
</tr>
<tr>
<td>Neuroblastoma</td>
<td>NB</td>
<td>10C</td>
</tr>
<tr>
<td>Ornithine transcarbamylase deficiency</td>
<td>OTC</td>
<td>10C</td>
</tr>
<tr>
<td>Other variant Hb-pathies (including Hb E)</td>
<td>Var Hb</td>
<td>10C</td>
</tr>
<tr>
<td>Phenylketonuria</td>
<td>PKU</td>
<td>8AS-8AT</td>
</tr>
<tr>
<td>Pompe disease</td>
<td>POMPE</td>
<td>10C</td>
</tr>
<tr>
<td>Propionic acidemia</td>
<td>PA</td>
<td>8AU-8AV</td>
</tr>
<tr>
<td>Severe combined immunodeficiency</td>
<td>SCID</td>
<td>10C</td>
</tr>
<tr>
<td>Short-chain acyl-CoA dehydrogenase deficiency</td>
<td>SCAD</td>
<td>8AW-8AX</td>
</tr>
<tr>
<td>Sickle cell anemia (Hemoglobin SS disease)</td>
<td>Hb SS</td>
<td>8AY-8AZ</td>
</tr>
<tr>
<td>Smith-Lemli-Opitz syndrome</td>
<td>SLO</td>
<td>10C</td>
</tr>
<tr>
<td>Trifunctional protein deficiency</td>
<td>TFP</td>
<td>8BA-8BB</td>
</tr>
<tr>
<td>Turner syndrome</td>
<td>TURNER</td>
<td>10C</td>
</tr>
<tr>
<td>Tyrosinemia type I</td>
<td>TYR I</td>
<td>8BC-8BD</td>
</tr>
<tr>
<td>Tyrosinemia type II</td>
<td>TYR II</td>
<td>10C</td>
</tr>
<tr>
<td>Tyrosinemia type III</td>
<td>TYR III</td>
<td>10C</td>
</tr>
<tr>
<td>Very long-chain acyl-CoA dehydrogenase def.</td>
<td>VLCAD</td>
<td>8BE-8BF</td>
</tr>
<tr>
<td>Wilson disease</td>
<td>WD</td>
<td>10C</td>
</tr>
<tr>
<td>X-linked Adrenoleukodystrophy</td>
<td>ALD</td>
<td>10C</td>
</tr>
<tr>
<td>α1-Antitrypsin deficiency</td>
<td>α1AT</td>
<td>10C</td>
</tr>
<tr>
<td>β-Ketothiolase deficiency</td>
<td>βKT</td>
<td>8E-8F</td>
</tr>
</tbody>
</table>